Methods for real-time multiplex isothermal detection and identification of bacterial, viral, and protozoan nucleic acids

ABSTRACT

Herein disclosed are rapid real-time isothermal multiplex methods of detecting, identifying and quantifying bacterial, viral, and protozoan nucleic acids in a sample. These include contacting the sample with two or more sets of pathogen-specific reverse transcription loop-mediated isothermal amplification primers and novel oligofluorophores specific for the target bacterial, viral, and parasitic nucleic acids of interest such as human immunodeficiency virus, Ebola virus, Marburg virus, Yellow fever virus, hepatitis-B virus, Lassa fever virus, Plasmodium, hepatitis-C virus, hepatitis-E virus, dengue virus, Chikungunya virus, Japanese Encephalitis virus, Middle Eastern Respiratory Syndrome Corona virus, Mycobacterium, West Nile virus, Cytomegalovirus, Parvovirus, Leishmania, Trypanosoma, and Zika virus nucleic acids, under conditions sufficient to produce detectable real-time amplification signals in about 10 to 40 minutes. The amplification signals are produced by pathogen-specific fluorogenic labels included in one or more of the primers. Also, novel reaction and sample lysis buffers, primers, and kits for rapid multiplex detection, quantification, and identification of bacterial, viral, and protozoan nucleic acids by real-time isothermal amplification are herein disclosed.

PRIORITY CLAIM

This patent application claims priority from U.S. Provisional application Ser. No. 62/158,664 filed on May 8, 2015, the contents of which are incorporated herein by reference.

SEQUENCE LISTING

The sequence listing contained in the electronic file “2016-05-01 1464.8005_ST25.txt” created on May 2, 2016, comprising 60 KB is incorporated herein by reference”.

FIELD OF THE INVENTION

This disclosure relates to rapid methods for real-time multiplex detection and identification of human immunodeficiency virus, Ebola virus, Marburg virus, Yellow fever virus, hepatitis-B virus, Lassa fever virus, Plasmodium species, hepatitis-C virus, hepatitis-E virus, dengue virus, Chikungunya virus, Japanese Encephalitis virus, Middle Eastern Respiratory Syndrome Corona virus, Mycobacterium species, West Nile virus, Cytomegalovirus, Parvovirus, Leishmania species, Trypanosoma species and Zika virus nucleic acids, utilizing real-time quantitative isothermal amplification methods.

BACKGROUND OF THE INVENTION

Over the past several decades, humankind has been confronted with a plethora of infectious pathogens that present differential diagnostic challenges due to similar on-set clinical symptoms and lead to diseases that afflict millions of people globally. Clinicians and field health care workers have long desired portable diagnostic tools that rapidly provide multiple differential diagnostic data in order to implement targeted therapeutic intervention and monitor the trend of disease transmission through epidemiological surveillance. It is apparent that a need exists for a detection assay in fulfillment of this quest. Thus, several diagnostic tests including nucleic acid-based multiplex isothermal amplification methods have been developed and used to detect various pathogens. These detection formats, including some isothermal platforms, are rigid and inflexible and do not allow for rapid simultaneous detection and identification of pathogens. Also, such platforms hardly enable simultaneous quantitation of the pathogen load in an infected person. A further shortcoming of existing methods is their intermittent open-tube characteristic of performance that renders them prone to contamination. Therefore, the objective of this method is to provide a versatile and flexible pathogen detection platform that enables shuffling of detection components and real-time isothermal multiplexing for rapid detection, identification, and quantitation of bacteria, viruses, and protozoans, among other pathogens. A further object of this invention is to provide a commercially practicable detection method that is portable, inexpensive, and field-deployable. Furthermore, it is the objective of the present invention to provide a comparably sensitive and specific multiplexing detection system that will contribute to national and global public health safety; this would contribute to ensuring early diagnosis of multiple infectious diseases and simultaneous identification of their causative agents, thereby enabling timely therapeutic intervention as well as ensuring national and global public health security.

SUMMARY OF INVENTION

The need for a portable diagnostic tool for simultaneous detection of multiple pathogens cannot be overemphasized. Hence, a real-time multiplex, rapid, sensitive, and specific assay for simultaneous detection, identification, and quantification of pathogens has been developed namely, for human immunodeficiency virus (HIV), Ebola virus species (Zaire, Sudan, Tai-Forest, Reston, Bundibugyo), Marburg virus (MBV), Yellow fever virus (YFV), hepatitis-B virus (HBV), Lassa fever virus (LFV), Plasmodium species, hepatitis-C virus (HCV), hepatitis-E virus (HEV), dengue virus (DENV), Chikungunya virus (CHIKV), Japanese Encephalitis virus (JEV), Middle Eastern Respiratory Syndrome Corona virus (MERS CoV), Mycobacterium species (MTB), Severe Acute Respiratory Syndrome Corona virus (SARS CoV), West Nile (WNV) virus, Cytomegalovirus (CMV), Parvovirus (PAB19), Plasmodium species (PLM), Leishmania species (LE), Trypanosoma species (TRY), Zika virus (ZKV) and an array of other infectious pathogens. The assay is developed for laboratory as well as point-of-care and field epidemiological application so as to enable differential pathogen diagnosis, blood donor screening, early diagnosis of infections, and monitoring of therapeutic efficacy. This method contains procedures for detecting, differentiating and quantifying HIV, EBOV, MARV, HBV, HCV, CHIKV, MERS CoV, PAB19, CMV, JEV, TB, HEV, DENV, YFV, LFV, LE, MTB TRY, ZKV, and/or PLM in a biological sample, utilizing methods that include real-time (reverse transcription) and isothermal amplification (RT-LAMP). The method of this invention further includes a versatile and flexible platform that allows shuffling and organizing of detection components as duplex, triplex, multiplex, and/or “megaplex” isothermal assays for real-time quantitative detection, quantification, and identification of nucleic acids of multiple pathogens, and groups of phylogenetically related infectious organisms.

Also embodied in this method is the capability to distinguish different species, genotypes or serotypes of a pathogen. The method has been suitably employed to distinguish the major genotypes of hepatitis C virus (HCV) infection (FIG. 3) utilizing a single primer set.

Notably, this invention advances the art of nucleic acid amplification as it embodies a real-time procedure that shuffles reactions detection components, including multiple sets of pathogen-specific or gene-specific RT-LAMP oligonucleotides and a novel designed RT-LAMP fluorooligonucleotides of various fluorogenic chemistries. These oligonucleotides and fluorooligonucleotide sets within SEQ ID No 1-306 hybridize with the target nucleic acid in a closed-tube single-reaction mixture, rapidly amplifies the nucleic acids in real-time under isothermal mechanism, and simultaneously produce real-time detectable reaction signals (such as melt, amplification and/or dissociation curves) that are indicative of detection as well as used to identify and quantitate the following pathogens (HIV, EBOV, MARV, HBV, HCV, CHIKV, MERS CoV, PAB19, CMV, JEV, MTB, HEV, DENV, YFV, LFV, LE, ZKV, TRP, and/or PLM) and their species or subtypes in biological samples.

The oligonucleotides for detection of bacterial, viral, and parasitic (protozoan) nucleic acids by real-time multiplex RT-LAMP are herein disclosed and include primers for detection of HCV (such as SEQ ID NOs: 1-68), HBV nucleic acids (such as SEQ ID NOs: 69-86), HEV (such as SEQ ID NOs: 87-100), HIV nucleic acids (such as SEQ ID NOs: 101-112), WNV (such as SEQ ID NOs: 113-118), DENV (such as SEQ ID NOs: 119-130), CHIKV nucleic acids (such as SEQ ID NOs: 131-143), CMV nucleic acids (such as SEQ ID NOs: 144-150), PLM nucleic acids (such as SEQ ID NOs: 151-156), EBOV nucleic acids (such as SEQ ID NOs: 157-169), MARV (such as SEQ ID NOs: 170-175), YFV nucleic acids (such as SEQ ID NOs: 176-181), LE nucleic acids (such as SEQ ID NOs: 182-187), LFV nucleic acids (such as SEQ ID NOs: 188-209), MTB nucleic acids (such as SEQ ID NOs: 210-221), MERS CoV nucleic acids (such as SEQ ID NOs: 222-235), PAB19 nucleic acids (such as SEQ ID NOs: 236-246), JEV nucleic acids (such as SEQ ID NOs: 247-258), SARS CoV nucleic acid (such as SEQ ID NOs: 259-276), TRY nucleic acid (such as SEQ ID NOs: 277-294), and ZKV (such as SEQ ID NOs: 295-306) are herein provided. Diagnostic kits including one, two, three, or more sets of real-time RT-LAMP primers and novel fluorooligonucleotides are also herein disclosed.

According to the method of this invention, nucleic acid extracted from biological samples are amplified in real-time under defined isothermal conditions between about 40° C. and 70° C., utilizing a novel and special lysis-amplification solution or reaction buffer (herein referred to as the Lysis Reaction Buffer—LRB) on a portable real-time multichannel fluorospectrophotometric heating system or device that produces live test results in real-time within about 10 to 40 minutes.

This disclosure also embodies methods utilizing heat-treatment and novel lysis buffer-treatment of biological samples, sets of enzymes to facilitate strand displacement of nucleic acid and for hybridization of reporters/fluorophores, and substrate materials to directly amplify nucleic acid without further extraction of the nucleic acid. Results are read in real-time on a portable device and transmitted to a smartphone or an electronic tablet through wireless electronic application. The method of this invention provides that the detection-device will provide simple on-screen quantitative amplification graphs or curves in real time in the form of dissociation, amplification and or melting curves that correspond to pathogen-assigned fluorogenic detection of specific nucleic acid as well as provide quantitative pathogen load. Also provided by this method is the instant naked-eye visualization of test results by the fluorogenic colors emitted by each pathogen-specific or pathogen-assigned fluorogenic probes.

Herewith provided from the foregoing disclosure are detailed descriptions as depicted by the following figures.

BRIEF DESCRIPTION OF THE DRAWINGS AND FIGURES

A vivid understanding of the key features of the above summarized invention may be facilitated by the following figures and drawings which demonstrate the method and system of the invention. Although these figures and drawings understandably depict preferred embodiments of the invention, they should not be construed as limiting its scope with regard to other embodiments which the invention is capable of contemplating. Herein, some of the following figures and illustrations are submitted in color.

FIG. 1 shows a flow chart demonstrating a schematic procedure for pathogen detection, identification, quantitation, and approximate duration.

FIG. 2 is a digital image that demonstrates detection of HCV genotypes 1-6 (FIGS. 2A and 2C) detected with separate sets of universal oligonucleotides as shown by the presence of identical ladder-like banding patterns. Note the absence of ladder-like patterns in the no-template control (NTC), Dengue virus (D or DNV), West Nile virus (W or WNV), Human immunodeficiency virus (HIV), and Hepatitis B virus (HBV). M=100 bp marker. FIGS. 2B and 2D are UV-visualization of detected pathogens as demonstrated by intense fluorescence glow of DNA intercalating dye in hepatitis C virus (HCV) genotype 1-6, but not in the control samples.

FIG. 3 is a digital image that shows detection and genotype identification of various hepatitis C virus (HCV) genotypes 1, 3, 4, 5, and 6 by a single primer-set and demonstrates distinct ladder-like banding patterns that are unique to each HCV genotype detected in duplicate and illustrated by color lines between the duplicates. Note that NTC=no-template control, NC=negative control plasma, and M=100 bp marker.

FIG. 4 is a digital image that demonstrates assay specificity of the HCV-specific primers and results of inhibition test performed. This figure shows detection of HCV-RNA in lanes 5-7 in the presence of HIV-RNA, HBV-DNA, and HIV-RNA alone or in combination; lanes 5-7 demonstrate HCV detection by the presence of ladder-like banding pattern which are similar to the HCV positive control in lane 4, and the absence of banding pattern in lanes 1-3. Note that NTC=no template control, HIV=human immunodeficiency virus (10⁶ IU/r×n), HBV=hepatitis B virus (10⁵ IU/r×n), HCV=hepatitis C virus (10³ IU/r×n), M=100 bp marker.

FIG. 5 is a digital image that shows detection sensitivity evaluated by serial dilution of HCV-RNA (10⁵-0.1 IU/r×n). The assay detected down to 10 IU/r×n of RNA (lane 8) and demonstrated a fluorescence glow of DNA intercalating dye that is corresponding to the amount of nucleic acid detected (lanes 3-8). Note that NTC=no-template control, NC=negative plasma control, M=100 bp marker, and IU/r×n=International Unit per reaction.

FIG. 6 is a digital image that shows time-course of detection and demonstrates the time point at which detection occurs. This was evaluated using 50 and 10 IU/r×n of HCV RNA at defined time points over a 60-minute reaction period. Electrophoretic analysis demonstrated detection of 50 IU of HCV-RNA at 40-minutes, while 10 IU/r×n of was detected at 60-minutes. Note that NTC=no-template control, M=100 bp marker, and IU/r×n=International Unit per reaction.

FIG. 7 demonstrates detection specificity and identification of Chikungunya virus (CHIKV) by isothermal amplification (lanes 4 and 5), using two dilutions (5000 and 500 copies per reaction); M=100 bp marker; NTC=non template control (lane 1); D=Dengue virus (lane 2); W=West Nile virus (lane 3).

FIG. 8 are digital images that demonstrate the multiplex detection and specificity of the HIV pathogen-specific fluorogenic oligonucleotides that detect only HIV nucleic acid as seen in FIG. 8B (lanes 4 to 6 triplicate samples) with brighter fluorescence on naked-eye visualization of reaction tubes. As seen in lanes 4-11, all pathogens are detected on gel electrophoresis because of the presence of their specific primers in the multiplex reaction mixture. FIG. 8D demonstrates detection only of the triplicate West Nile virus (WNV) samples by the WNV-specific fluorooligonucleotide which is further demonstrated by a brighter fluorescence glow in the triplicate WNV samples in lanes 9, 10, and 11. Note: M=100 bp marker; NTC=non-template control; CMV=cytomegalovirus; PV=parvovirus; hepatitis-E virus (HEV); dengue virus (DENV); HCV=hepatitis C virus. The fluorooligonucleotides were labeled with 6-FAM (5′) and BHQ1 (3′).

FIGS. 9A and FIG. 9B are illustrations of a real-time multiplex isothermal detection and simultaneous identification of four viral pathogens (HIV, HBV, WNV, and HCV) by their respective primers and specific fluorogenic oligonucleotides of each pathogen. This is shown by the real-time amplification dissociation curves of the respective pathogens. The amplification show the following: (a) internal positive control; (1) HIV=human Immunodeficiency virus; (2) HBV=hepatitis B virus; (3) WNV=West Nile virus; (4) HCV=hepatitis C virus; and NP=negative (healthy) human plasma).

FIGS. 10A, 10B, 10C and 10D Illustrate real-time multiplex isothermal detection and identification of pathogens (including HIV, HBV, WNV, PLM, CMV, DENV, TRY, PV, and LE) by their respective primers and specific fluorogenic oligonucleotides of each pathogen. This is shown by the real-time amplification dissociation curves of the respective pathogens. The amplification show detection of the following: (a) internal positive control; (1) HIV=human Immunodeficiency virus; (2) HBV=hepatitis B virus; (3) WNV=West Nile virus; (4) PLM=Plasmodium (malaria); (5) CMV=cytomegalovirus; (6) DENV=dengue virus; (7) TRY=Trypanosoma, (8) LE=Leishmania; PV=Parvovirus; and, NP=negative (healthy) human plasma.

FIG. 11 Illustrates thermo-stability and amplification efficiency of the novel Lysis Reaction Buffer (LRB) after thermo-stressed stability test and used in real-time isothermal amplification after 12 months of room-temperature storage. Lanes 5-7 demonstrate amplification of HCV (hepatitis C virus); M=100 bp marker; and NP=negative (healthy human) plasma in lanes 1, 2, and 3.

FIG. 12 is a digital image which demonstrates the multifaceted application and utility of the new Lysis Reaction Buffer (LRB) used for isothermal amplification in the top panel and for regular (RT) PCR reaction in the bottom panel to detect hepatitis B virus (HBV) in lane 5. Note that M=100 bp marker; NC=non-template control; PC=positive control HBV DNA; and, NS=negative sample.

FIG. 13 is a digital image which shows efficient utility of the novel Lysis buffer. The lysis buffer was added to the HCV-infected plasma standards in a 1:3 ratio and incubated at room temperature for approximately 10 minutes. Then 10 μL of the resulting lysate was applied directly to the amplification mixture for detection of HCV RNA which is demonstrated by the presence of ladder-like banding patterns in lanes 3 to 8. Note that hepatitis C virus control (lane 3); M=100 bp marker; NTC=no-template control in lane 1; NP=negative sample (lane 2).

FIG. 14 illustrates the novel design of isothermal real time RT-LAMP fluorooligonucleotide of the F3, R3, LR, LF, FIP, and RIP. For example, the SEQ LF oligonucleotide is designed as bi-labeled loop-fluorescent-probe that is held in a hairpin-loop conformation by about 4-7 nucleotides long complementary stem-sequences at both 5′-3′ ends (or vice versa) and tagged with desirable reporter-fluorophore or quencher. Fluorophores may including Cy5, Cy5.5, Cy3, 6-carboxyfluorescein (6-Fam), tetrachlorofluorescein (Tet), or Texas-Red or other desirable reporter dyes, while quenchers may include Tamara, DABCYL, black hole quencher-1, 2, and 3 (BHQ1, 2, and 3) or other desirable quenchers. FIG. 14 also illustrates a probe hybridized to its target nucleic acid strand, wherein florescence is emitting and utilized for detection and identification of pathogen a well as quantitation of pathogen burden. (a)=F2 position of target nucleotide on gene sequence; (b)=nucleotide sequence of fluorooligonucleotide comprising of a fluorophore (F) held by the boxed complementary stem-sequences at the 5′-terminus, while a quencher (Q) is held by another boxed complementary stem-sequence at the 3′-terminus; (c)=position of the F1c portion of the FIP primer as illustrated on the 5′ non-coding region of the Zika virus (ZKV) gene.

OLIGONUCLEOTIDE SEQUENCES

Any nucleic acid and amino acid sequences herein listed are shown using standard letter abbreviations for nucleotide bases and amino acids. In some cases, only one strand of each nucleic acid sequence is shown, while the complementary strand is understood as included by any reference to the displayed strand.

SEQ ID NOs: 1-68 are nucleic acid sequences of exemplary HCV RT-LAMP primers.

SEQ ID NOs: 69-86 are nucleic acid sequences of exemplary HBV LAMP primers.

SEQ ID NOs: 87-100 are nucleic acid sequences of exemplary HEV RT-LAMP primers.

SEQ ID NOs: 101-112 are nucleic acid sequences of exemplary HIV RT-LAMP primers.

SEQ ID NOs: 113-118 are nucleic acid sequences of exemplary WNV RT-LAMP primers.

SEQ ID NOs: 119-130 are nucleic acid sequences of exemplary DENV RT-LAMP primers.

SEQ ID NOs: 131-143 are nucleic acid sequences of exemplary CHIKV RT-LAMP primers.

SEQ ID NOs: 144-150 are nucleic acid sequences of exemplary CMV LAMP primers.

SEQ ID NOs: 151-156 are nucleic acid sequences of exemplary PLM LAMP primers.

SEQ ID NOs: 157-169 are nucleic acid sequences of exemplary EBOV RT-LAMP primers.

SEQ ID NOs: 170-175 are nucleic acid sequences of exemplary MARV RT-LAMP primers.

SEQ ID NOs: 176-181 are nucleic acid sequences of exemplary YFV RT-LAMP primers.

SEQ ID NOs: 182-187 are nucleic acid sequences of exemplary LE LAMP primers.

SEQ ID NOs: 188-209 are nucleic acid sequences of exemplary LFV RT-LAMP primers.

SEQ ID NOs: 210-221 are nucleic acid sequences of exemplary MTB LAMP primers.

SEQ ID NOs: 222-235 are nucleic acid sequences of exemplary MERS CoV RT-LAMP primers.

SEQ ID NOs: 236-246 are nucleic acid sequences of exemplary PAB19 RT-LAMP primers.

SEQ ID NOs: 247-258 are nucleic acid sequences of exemplary JEV RT-LAMP primers.

SEQ ID NOs: 259-276 are nucleic acid sequences of exemplary SARS CoV RT-LAMP primers.

SEQ ID NOs: 277-294 are nucleic acid sequences of exemplary TRY RT-LAMP primers.

SEQ ID NOs: 295-306 are nucleic acid sequences of exemplary ZKV RT-LAMP primers.

DETAILED DESCRIPTION OF THE INVENTION I. Abbreviations

CHIKV Chikunguya virus

CMV cytomegalovirus

DENV Dengue virus

HBV hepatitis B virus

HCV hepatitis C virus

HEV hepatitis E virus

HIV human immunodeficiency virus

EBOV Ebola virus

F Fluorophore

IU international units

JEV Japanese encephalitis virus

LAMP loop-mediated isothermal amplification

LFV Lassa fever virus

LE Leishmania

NCR non-coding region

MARV Marburg virus

MERS CoV Middle Eastern Respiratory Syndrome Corona virus

MTB mycobacterium tuberculosis

PAB19 Parvovirus B19

PLM plasmodium

Q quencher

RFU relative fluorescence units

RT reverse transcriptase

(RT)-LAMP (reverse transcription)-loop-mediated isothermal amplification

SARS CoV Severe Acute Respiratory Syndrome Coronavirus

TRY Trypanosoma

UV ultraviolet

WNV West Nile virus

YFV Yellow fever virus

ZKV Zika virus

II. Definitions

Technical terminologies used herein are conventionally employed parlance in the field of molecular biology and amplification technology. These terms and methods provide a clearer description of the present disclosure and a guidance for those of ordinary skill in the art to practice the present disclosure. Publications, patent applications, patents, and/or other references mentioned herein are incorporated by reference for all purposes. Sequences associated with GenBank Accession Nos. mentioned herein are incorporated by reference as were present on Apr. 27, 2015, to the extent permissible by applicable rules and/or law. Although methods and materials similar or equivalent to those described herein can be used to practice or test the disclosed technology, suitable methods and materials containing specifics are described below. The materials, methods, and examples are illustrative only and not intended to be limiting. In order to facilitate review of the various embodiments of this disclosure, the following explanations of specific terminologies are provided:

Amplification: Is an exponential increase in the number of copies of a nucleic acid molecule, such as a gene or fragment of a gene, for example at least a portion of an HIV, HBV, HCV, DENV, CHIKV or WNV nucleic acid molecule. The products of an amplification reaction are called amplicons or amplification products. Amplification may be represented by a graphed curved such as dissociation curves or by bands (banding-pattern) on gel electrophoresis. For gene analysis or diagnostic purposes, amplification of nucleic acids from biological samples is performed in vitro utilizing techniques such as the polymerase chain reaction (PCR), real-time PCR, quantitative real-time PCR (qPCR), reverse transcription PCR (RT-PCR), quantitative RT-PCR (qRT-PCR), and loop-mediated isothermal amplification (LAMP; see Notomi et al., Nucl. Acids Res. 28:e63, 2000); reverse-transcriptase LAMP (RT-LAMP); and strand displacement amplification (see U.S. Pat. No. 5,744,311), among others. Common to these techniques is a process by which a sample (containing nucleic acid) is hybridized with primers. Under defined thermocyclic or isothermal condition, amplification occurs through strand displacement of template, primers annealing, and extension, thus resulting to an exponential production of millions of copies of a piece of nucleic acid.

CHIKV: Chikungunya virus (CHIKV) was first isolated following an outbreak in Tanzania in the 1950s (Ross. J Hyg (Loud), 54:177-191, 1956). CHIKV infection typically induced an acute onset of painful syndrome as characterized by polyarthralgia, fever, asthenia, headache, myalgia and skin rashes. CHIKV is an enveloped virus that possesses a single stranded, positive-sense RNA genome of 12 kilobases. CHIKV is transmitted by the Aedes mosquito, with Aedes aegypti and Aedes albopictus as the main vectors, while humans serve as host. Its mortality rate is rather low, but the epidemic potential of the virus is fearful due to the prolonged morbidity and the rapid spread of the virus. In 2004, the virus managed to claim global attention when it re-emerged and began spreading around the world. Exemplary CHIKV sequences include GenBank Accession Nos. FN295487, HQ846358, JF274082, and HW249780 which are incorporated by reference herein as present in GenBank on Apr. 27, 2015. Additional CHIKV species sequences can be identified by one skilled in the art.

CMV: Cytomegalovirus (CMV) is a leading cause of opportunistic infection causing substantial morbidity and mortality in transplant patients (Dummer et al., J. Infect. Dis. 152, 1182-1191, 1985) and HIV-infected patients who are immunocompromised (Drew, 1996). As a member of the family Herpesviridae, CMV establishes latency upon primary infection which occurs early in life in a majority of individuals (Britt and Alford, 1996). CMV can also cause asymptomatic infection. Exemplary CMV sequences include GenBank Accession Nos. BK000394, FJ527563, FJ491277, and FJ616285 which are incorporated by reference herein as present in GenBank on Apr. 27, 2015. Additional CMV species sequences can be identified by one skilled in the art.

Dengue virus (DENV): Dengue virus (DENV) is member of the family Flaviridae and is transmitted by the mosquito vector, Aedes aegypti. There are 4 different serotypes of the virus, namely, DENV-1, DENV-2, DENV-3, and DENV-4. It is estimated that yearly over 300 million people are infected with DENV. DENV infection causes dengue fever or dengue hemorrhagic fever (DHF) with symptoms including high fever, severe headache, severe joint, muscle, and bone pain, rash persistent vomiting, severe abdominal pain, and hemorrhagic manifestations such as ascites, pleural effusions, bleeding of internal organs or hemorrhagic shock. DENV nucleic acid and protein sequences are available in public databases, including GenBank. Examples of DENV sequences include GenBank Accession Nos. KM204119, AF180817, and KJ438296 (DEN-1); KP012546 and KC762677 (DEN-2); KJ643590, KF954949, and KF954946 (DEN-3); and KJ160504 and KJ160504 (DEN-4), all of which are incorporated by reference as included in GenBank on Apr. 27, 2015. Additional DENV species sequences can be identified by one skilled in the art.

Detectable labels: These are detectable compounds such as fluorophores, radioactive isotopes, fluorescein, etc., that are conjugated to another molecule to enable detection, identification, and quantitation of said molecules. For example, nucleic acids are labeled for various purposes and several methods are available for facilitating the labeling of nucleic acids (Marras. Methods Mol Biol, 335: 3-16, 2006; Sambrook and Russell, in Molecular Cloning: A Laboratory Manual, 3^(rd) Ed., Cold Spring Harbor Laboratory Press (2001).

Ebola virus (EBOV): Ebola viruses (EBOV) causes Ebola Virus Disease (EVD), a severe haemorrhagic fever that is characterized by a high case-fatality rate around 50-90%. EBOV is an enveloped, non-segmented, RNA negative stranded virus of the family of Filoviridae. The viral genome, approximately 19 kilobases long, contains seven genes transcribed by the complex of the RNA-dependent RNA polymerase (L and VP35 proteins). Ebola virus was first discovered in 1976 in northern Zaire (now the Democratic Republic of Congo) and southern Sudan. There are 5 EBOV species known to date: (ZEBOV, emerged first in Zaire) and Sudan ebola virus (SUDV), discovered in 1976; Reston ebola virus (RESTV), discovered in 1989; Taï Forest virus (TAFV), discovered in 1994; and Bundibugyo virus (BDBV), discovered in 2007 (Feldmann and Geisbert, The Lancet. 377:849-862, 2011). Four Ebola virus species, ZEBOV, SUDV, TAFV, and BDBV, are known to be pathogenic in humans. The virus is zoonotic and is transmitted to humans from animals. Fruit bats are probable virus reservoir (Leroy et al., Nature. 438:575-576, 2005). EBOV nucleic acid and protein sequences are available in public databases, including GenBank. Exemplary EBOV sequences include GenBank Accession Nos. NC002549 and KM233049 (ZEBOV), EU338380 (SUDV), AF522874 (RESTV), NC014372 (TAFV), KC545396 (BUDBV), which are incorporated by reference herein as present in GenBank on Apr. 27, 2015. Additional EBOV species sequences can be identified by one skilled in the art.

Fluorophore: A fluorophore is a fluorescent chemical compound that can re-emit light upon light excitation of a specific wavelength. These compounds are used alone, as a tracer-molecules in fluids, as a dye for staining of certain cellular structures, as a substrate of enzymes, or as a probe or indicator for detecting nucleic acids. Employed in confocal microscopy, immunohistochemistry, and nucleic acid amplification methods, fluorophores are also part of the larger class of luminescent compounds (Liu et al., “Fluorophores and Their Applications as Molecular Probes in Living Cells”, Curr. Org. Chem. 17: 564-579, 2013). Fluorophores can be attached to nucleic acid sequences either as “donor” or “acceptor” and may function on the biochemical mechanism of fluorescence energy transfer to emit, quench the fluorescence of other fluorescent dyes or to relay their fluorescence at much longer wavelengths. The acceptor fluorophores absorb energy from donor fluorophores within wavelength spanning between about 300 to approximately 900 nm. The following are examples of fluorophores that can be used in the probes and primers disclosed herein and are known to those skilled in the: acridine and acridine isothiocyanate, 4-amino-N-[3-vinylsulfonyl)phenyl]naphthalimide-3,5 disulfonate (Lucifer Yellow VS); Brilliant Yellow; coumarin and derivatives such as coumarin, 7-amino-4-methylcoumarin (AMC, Coumarin 120), 7-amino-4-trifluoromethylcouluarin (Coumaran 151); cyanosine; 4′,6-diaminidino-2-phenylindole (DAPI); ethidium; -fluorescein and derivatives such as 5-carboxyfluorescein (FAM), 2′7′-dimethoxy-4′5′-dichloro-6-carboxyfluorescein (JOE), fluorescein, 6-carboxy-fluorescein (HEX), and TET (tetramethyl fluorescein); Phenol Red; rhodamine and derivatives such as 6-carboxy-X-rhodamine (ROX), rhodamine (Rhod), rhodamine B, rhodamine 123, rhodamine X isothiocyanate, N,N,N′,N′-tetramethyl-6-carboxyrhodamine (TAMRA); sulforhodamine B; sulforhodamine 101 and sulfonyl chloride derivative of sulforhodamine 101 (Texas Red); LightCycler Red 640; Cy5.5; and Cy56-carboxyfluorescein; other fluorophores include Cy3; Cy5, VIC (from Applied Biosystems); LC Red 640; LC Red 705; and Quasar® 570, Quasar® 670, CalRed 590, CalRed 610, CalRed 615, CalRed 635, CalGreen 520, CalGold 540, and CalOrange 560 (from Biosearch Technologies, Novato, Calif.). One skilled in the art can select additional fluorophores from commercial vendors such as Integrated DNA Technologies (Coralville, Iowa) and Molecular Probes or Life Technologies (Carlsbad, Calif.). In a particular example, the following acceptor fluorophores can be attached to nucleic to quench or diminish the emission of a reporter fluorophore: Dabcyl, QSY7, and QSY33 (from Molecular Probes), Black Hole Quenchers™ such as BHQ1, BHQ2, and BHQ3, Eclipse™ Dark Quencher (from Epoch Biosciences), or Iowa Black™ (Integrated DNA Technologies

Hepatitis B virus (HBV): HBV is a DNA virus with a circular genome of partially double-stranded DNA that is a member of the family Hepadnaviridae. HBV causes acute disease, characterized by liver inflammation, vomiting, and jaundice, as well as chronic infection which may lead to cirrhosis or hepatocellular carcinoma. There are eight genotypes of HBV (A-H). HBV-A is most commonly found in the Americas, Africa, India, and Western Europe, HBV-B and HBV-C are most commonly found in Asia and the United States and HBV-D most commonly found in Southern Europe, India, and the United States. The HBV genotypes differ by at least 8% of their sequence across the genome (Okamoto et al., J. Gen. Virol. 69:2575-2583, 1988). HBV nucleic acid and protein sequences are available in public databases, including GenBank. Exemplary HBV sequences include GenBank Accession No. AB116094 (HBV-A), AF121247 (HBV-B), AB670304 (HBV-C), AB090269 (HBV-D), HM363603 (HBV-E), AB036912 (HBV-F), JX849644 (HBV-G), and AP007261 (HBV-H), all of which are incorporated by reference herein as present in GenBank on Apr. 27, 2015. Additional HBV species sequences can be identified by one skilled in the art.

Hepatitis C virus (HCV): Hepatitis C virus (HCV) is a single-stranded RNA virus of the Flaviviradae family and there are 7 major genotypes with 67 subtypes found in different regions of the world (Smith et al., Hepatology. 59: 318-327, 2014; Moratorio et al., Virol J. 4: 79, 2007). Transmitted through modes such as injection drug use (IDU), unsafe injections, needle-stick, and mother-to-fetal, infection with HCV may be asymptomatic for several years and lead to chronic-active hepatitis and hepatocellular carcinoma (Ghany et al., Hepatology. 4: 1335-1374, 2009). Approximately 170 million people globally are infected with HCV. According to the US Centers for Disease Control and Prevention (CDC), about 3.2 million people are infected with HCV in the United States, wherein HCV genotypes 1 and 2 account for majority of infections. Progression of HCV-induced liver damage and response to antiviral therapy is genotype dependent as HCV genotypes 1b is associated with severe liver disease than other genotype. HCV nucleic acid and protein sequences are available in public databases, including GenBank. Exemplary HCV sequences include GenBank Accession Nos. AF009606 and AF333324 (HCV-1), D00944 (HCV-2), and HQ228207 (HCV-3), JX227959 (HCV-4), Y13184 (HCV-5), DQ480524 (HCV-6) all of which are incorporated by reference herein as present in GenBank on Apr. 27, 2015. Additional HCV species sequences can be identified by one skilled in the art.

Hepatitis E virus (HEV): HEV is a small, single-stranded, non-enveloped RNA hepatotropic virus currently classified in the genus Hepevirus (Purcell et al., J Hepatol. 48:494-503, 2008). HEV is transmitted via the faecal-oral route and may be blood-borne. At higher risk of infection with HEV are immunocompromised individuals and organ transplant recipients. HEV causes outbreaks that have been linked to waterborne sources in developing countries in the Northern and Central regions of Africa, South and Central America and Southeast Asia. HEV infection which was thought to be imported in the developed countries is otherwise demonstrated to be prevalent in the United States, Europe and Japan (Dong et al., J Clin Microbiol. 49:4164-4172, 2011). There are four genotypes of HEV (genotypes 1-4), some of which infect only humans, animals, or both. Genotypes 1 and 2 infect humans, but genotypes 3 and 4 infect humans and animals, predominantly pigs, thereby demonstrating zoonotic and cross-species transmission (Mushahwar et al., J. Med Virol, 2008). HEV nucleic acid and protein sequences are available in public databases, including GenBank. Exemplary HEV sequences include GenBank Accession No. AF010126 (HEV-1), M74506 (HEV-2), AF060668 and HQ389543 (HEV-3), and GU206557 (HEV-4) and are incorporated by reference herein as present in GenBank on Apr. 27, 2015. Additional HEV species sequences can be identified by one skilled in the art.

Human immunodeficiency virus (HIV): The human immunodeficiency virus (HIV) is a lentivirus, a subgroup of retrovirus that causes the acquired immunodeficiency syndrome (AIDS). HIV is composed of two copies of positive single-stranded RNA that codes for genes enclosed by a conical capsid (Weiss. Science, 260: 1273-1279, 1993). The virus has two types, namely HIV-1 and HIV-2. HIV is transmitted through transfusion of blood, semen, vaginal fluid, pre-ejaculate, or breast milk of an infected person. The virus primarily infects and depletes the CD4+ T-cells and other cells of the immune system (Sigal et al., Nature 477: 95-98, 2011). HIV/AIDS engenders a condition in humans that is characterized by the progressive failure of the immune system and allows life-threatening opportunistic infections (the AIDS related complexes—ARC) and some forms of cancers (e.g. Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer) (Fischl et al., N Engl J Med. 317:185-191, 1987; Friedman-Kien. J. Am. Acad. Dermatol. 5: 468-471, 1981). HIV infection is diagnosed by means of serological methods such as Western blot which detects antibody to the viral proteins and nucleic acid test such as RT-PCR which detects viral RNA in blood (Chou et al., Annals of Internal Medicine 143: 55-73, 2005). To date, about 31 antiretroviral drugs (ARVs) are approved by the US Food and Drug Administration to treat HIV infection. While there is no cure for HIV/AIDS infection, the antiviral treatments suppress the virus, even to undetectable levels, thus enabling infected persons to lead healthier and longer lives. Nucleic acid and protein sequences of HIV are available in public GenBank and the HIV Database at the Los Alamos National Laboratory (www.hiv.lanl.gov/). Exemplary sequences in GenBank include the following: KF735874, EU541617, and JN248357 (HIV-1); X05291, AF208027, M30502, and DQ307022 (HIV-2). Additional HIV species sequences can be identified by one skilled in the art.

Hybridize: Hybridization is a phenomenon in molecular biology, in which single-stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) molecules anneal to complementary DNA or RNA under controlled temperature conditions. These strands are complementary to each other as in the case of nucleic acid amplification reaction in which primers and probes are utilized.

Isolate: A biochemical process by which nucleic acid (e.g. genomic DNA, total RNA or micro-RNA) are separated and purified from biological samples such as blood components. An “isolated” biological component (such as a nucleic acid) has been substantially separated or purified away from other biological components in which the component naturally occurs, such as other chromosomal and extrachromosomal DNA, RNA, and proteins. Utilizing various methods of purification (silica-based columns, or phenol-chloroform) methods, isolated nucleic acids may be up to 99.9% pure.

Japanese encephalitis virus (JEV): JEV is a mosquito-borne flavivirus known to be endemic in Asia, extending to India and Pakistan in the west, where it is a leading cause of non-bacterial encephalitis. JEVcauses an estimated annual number of 30,000-50,000 cases worldwide (Mackenzie et al. Nat Med. 10:S98-109, 2004). The majority of the infections are subclinical, but up to 30% of symptomatic patients die, and 30% of the survivors have persistent neurological sequelae. The life cycle of JEV includes Culex mosquitoes and water birds or pigs, but JEV also infects a wide range of other vertebrates. In addition to humans, horses may develop encephalitis and are considered dead-end hosts for JEV transmission. JEV sequences include GenBank Accession Nos.: JF706284, JN711459, JF706285, and AF080251, all of which are incorporated by reference as included in GenBank on Apr. 27, 2015. Additional JEV species sequences can be identified by one skilled in the art.

Leishmania (LE): Leishmaniasis is a parasitic disease affecting millions of people mainly on the Indian Sub-continent It is the main cause of cutaneous Leishmaniasis (CL) and visceral leishmaniasis (VL) in the Old World. Parasites are transmitted by Phlebotominae sandflies after blood-feeding on infected mammalian hosts. CL is widely spread in the developing world, affecting people in 88 countries with 1.5 million new cases reported each year (Alvar et al., PLoS One. 7:e35671, 2012; Desjeux. Comp Immunol Microbiol Infect Dis. 27: 305-318, 2004). CL usually produces ulcers on the exposed parts of the body that often leave disfiguring scars, which in turn, can cause serious social prejudice. Visceral leishmaniasis (VL) is considered as one of the most neglected tropical diseases. On the Indian sub-continent, VL is mainly caused by the intracellular protozoan parasite Leishmania donovani and transmitted exclusively by the bite of the sandfly, Phlebotomous argentipes. The annual incidence worldwide is approximately 0.2 to 0.4 million cases with over 60% of the world's VL cases occurring in India, Bangladesh and Nepal (WHO: Regional Technical Advisory Group on Kala-azar Elimination. Report of the first meeting, Manesar, Haryana, 20-23 Dec. 2004. New Delhi: WHO Regional Office for South-East Asia; 2005). LE sequences include GenBank Accession Nos.: GQ332356, AF308685, KJ417491, and AB678350, all of which are incorporated by reference as included in GenBank on Apr. 12, 2015. Additional LE species sequences can be identified by one skilled in the art.

Lassa fever virus (LFV): Lassa fever, a viral hemorrhagic fever, is caused by the Lassa virus. The disease is endemic to a large region of West Africa, where 100,000-300,000 cases have been estimated to occur yearly (McCormick et al., J Infect Dis. 155:445-455, 1987). More than 20 cases have been imported to the United States, Canada, United Kingdom and Japan since 1969, when the disease was first recognized (Macher and Wolfe. Emerg Infect Dis, 12:835-837, 2006). The viral hemorrhagic fever reportedly has a 69% case fatality rate in hospitalized patients. LAV sequences include GenBank Accession Nos.:KM821843, HQ688672, and GU481073, all of which are incorporated by reference as included in GenBank on Apr. 12, 2015. Additional LAV species sequences can be identified by one skilled in the art.

Loop-mediated isothermal amplification (LAMP): A one temperature DNA amplification method that utilizes two or three pairs of primers, DNA strand displacement enzymes to catalyze the reaction. The method is a single-step amplification reaction utilizing a DNA polymerase with strand displacement activity (e.g., Notomi et al., Nucl. Acids. Res. 28:E63, 2000; Nagamine et al., Mol. Cell. Probes 16:223-229, 2002; Mori et al., J Biochem. Biophys. Methods 59:145-157, 2004). The amplification reaction produces a stem-loop DNA with multiple inverted repeats of the target nucleic acid sequence. Reverse transcriptase can be added to the reaction for amplification of RNA target sequences, a process referred to as RT-LAMP.

Marburg virus (MARV): Marburg fever is a viral hemorrhagic illness caused by the Marburg virus. The virus was first isolated in Marburg, Germany in 1967 after which several outbreaks have been reported in the Democratic Republic of the Congo and Angola (Slenczka and Klenk, Journ of Infect Dis. 196:S131-135, 2007; Towner et al., J Virol. 80:6497-6516, 2006) with case fatality rates approaching 90%. Travelers visiting Uganda have also imported the virus into the Netherlands and the United States (Timen. Emerg Infect Dis. 15:1171-1175, 2009; Fujita et al., MMWR Morb Mortal Wkly Rep, 58:1377-1381, 2009). MARV sequences include GenBank Accession Nos.: KP117261, KC545388, JX458851, FJ750959, and DQ447658, all of which are incorporated by reference as included in GenBank on Apr. 27, 2015. Additional MARV species sequences can be identified by one skilled in the art.

Middle East respiratory syndrome coronavirus (MERS CoV): Middle East respiratory syndrome coronavirus (MERS-CoV) is a viral infection characterized by history of fever, cough, expectoration, and shortness of breath. It is a Coronavirus that was initially identified from a 60-year-old Saudi man who was admitted to a private hospital in Jeddah on Jun. 13, 2012 (Zaki et al., N Engl J Med. 367:1814-1820, 2012). Since the initial description, a total of 834 laboratory-confirmed cases of infection with MERS-CoV including 288 (34.5%) deaths were reported to the World Health Organization (WHO). MERS-CoV sequences include GenBank Accession Nos.: KF600647 and KF917527, both of which are incorporated by reference as included in GenBank on Apr. 12, 2015. Additional MERS-CoV species sequences can be identified by one skilled in the art.

Parvovirus B19 (PAB19): Parvovirus B19 (B19V), is the causative agent of erythema infectiosum, otherwise known as the “fifth disease”. It may be present in blood and in plasma products, infect blood recipients, and cause severe disease (Dodd. Transfusion. 51:1878-1879, 2011). B19V is a small non-enveloped single-stranded-DNA genome (length 5-6 kb) of the Parvoviridae family. Based on isolates having nucleotide divergence greater than about 10%, three B19V genotypes have been identified. Genotype 1 is the most prevalent type and circulates worldwide and is the B19V prototype. Genotype 2 viruses are found in plasma donations from Europe and North America. Genotype 3 has been found predominantly in West Africa (Ghana), but has also been found in samples from Europe, Asia, and South America, mainly Brazil (Candotti et al. J Virol. November; 78:12169-12178, 2004). PAVB19 sequences include GenBank Accession Nos.: AB126271, DQ234779, and AY582125 which are incorporated by reference as included in GenBank on Apr. 12, 2015. Additional PABV19 species sequences can be identified by one skilled in the art.

Plasmodium (PLM): Plasmodium is a parasitic protozoan that causes malaria infection. Several Plasmodium species (malariae, vivax, ovale, and falciparum) infect humans and other animals, and are transmitted by mosquitoes of the Anopheles genus. Malaria infection occurs around the world especially in Africa, Asia, and South America (Alexandre et al., Emerg Infect Dis. 16:1611-1614, 2010; Camara et al., Malar J. 14:60, 015; Upadhyayula, et al., PLoS One. 10: e0119514, 2015). PLM sequences include GenBank Accession Nos.: HQ283210, HQ283218, KF696372, and KJ170107 which are incorporated by reference as included in GenBank on Apr. 27, 2015. Additional PLM species sequences can be identified by one skilled in the art.

Primer: A primer is a strand of short nucleic acid sequences (generally about 10, 20, 40 or more base pairs) that serves as a starting point for DNA synthesis or cDNA synthesis from RNA. This biochemical process occurs during amplification or replication.

Probe: A probe is a complementary nucleic sequences of about 10 or more nucleotides long and to which fluorophores or other detectable molecules are attached.

SARS CoV: Severe acute respiratory syndrome Coronavirus (SARS CoV) is an emerging infectious disease that has affected many countries since it was first discovered in Asia in 2003 (WHO. Wkly Epidemiol Rec; 78:73-74, 2003). SARS CoV, which is transmitted through coughing out of respiratory droplets, is genetically related to the coronaviruses that are characterized by the presence of a single-stranded positive-sense RNA genome of about 30 kb in length (Marra et al., Science. 300:1399-1404, 2003; Drosten et al., N Engl J Med. 348:1967-1976, 2003). During the 2003 outbreak, SARS spread across five continents and had a cumulative total of 8464 cases and 799 deaths by May that year. SARS CoV sequences include GenBank Accession Nos.: FJ950407, AY545919, JX163925, and DQ497008 which are incorporated by reference as included in GenBank on Apr. 27, 2015. Additional SARS CoV species sequences can be identified by one skilled in the art.

Sample: A biological specimen that contains nucleic acids such as genomic DNA, complementary DNA), messenger RNA total RNA, small inhibitory RNA, etc. Samples could be specimens such as blood components, sputum, urine, vomitus, tissues, organs, and cells among others.

“Shufflex”: A term describing a procedure whereby assay reagents such as (fluoro)-oligonucleotides and reaction components are flexibly arrange, rearranged, or shuffled around, and formulated to detect, identify, and quantitate a group of pathogens that are either phylogenically related or present similar clinical symptoms.

Subject: Any multi-cellular vertebrate organism, such as human and non-human mammals (including non-human primates). In one example, a subject is known to be or is suspected of being infected with one or more viruses, bacteria, and/or parasites.

Trypanosoma (TRY): Trypanosoma is the etiological agent of American and African trypanosomiasis. There are several known species among which Trypanasoma cruzi (T. cruzi), Trypanosoma bruecei (T. burcei), Trypanosoma gambiense (T. gambiense), and Trypanosoma rhodesiense (T. rhodesiense) are the most common. For example, T. cruzi, found in the Americas, is the cause of Chagas' disease, which affects approximately 16 to 18 million people in 21 countries in Central and South America. As a result of human migration from Latin America, the disease has spread to the United States and Canada, and as far as Europe and Australia in recent years. (Schmunis. Mem Inst Oswaldo Cruz. 102 Suppl 1:75-85, 2007). Trypanosoma is transmitted through insect bites to humans and other animals, with T. burcei, T. gambiense, and T. rhodesiense causing sleeping sickness Africa.

Mycobacterium Tuberculosis (MTB): Tuberculosis (TB), caused by Mycobacterium species is one of the leading causes of death worldwide. According to the World Health Organization (WHO), approximately 9 million people developed TB in 2013 and about 1.5 million died from the disease (WHO. Global tuberculosis report 2014, 2014). TB is transmitted by human-to-human or animal (Mycobacterium bovis which infects animals) contact through inhalation of contaminated droplets released from the lungs of an infected person. The WHO estimated that 3.5% of new and 20.5% of previously treated cases were multidrug-resistant strains of Mycobacterium tuberculosis (MDR-TB). Hence, irrespective of evidence that TB is slowly declining, the emergence and spread of multidrug-resistant strains of Mycobacterium tuberculosis represents a major public health challenge to the global control of the disease. MTB sequences include GenBank Accession Nos.: AL123456, AP010918, CP010873, and BX248333 which are incorporated by reference as included in GenBank on Apr. 27, 2015. Additional MTB species sequences can be identified by one skilled in the art.

West Nile virus (WNV): WNV is an RNA virus of the Flaviviridae family and is related to other important human pathogens, including dengue viruses, yellow fever viruses, and Japanese encephalitis viruses. WNV is an enveloped single-stranded, positive sense virus of an approximately 11-kb RNA genome. This flavivirus has emerged as a significant cause of viral encephalitis globally. WNV is transmitted by mosquitoes and infects humans and causes diseases in other animals including horses (Hayes et al., Emerg Infect Dis 0.11:1167-1173, 2005). Infection of humans is associated with a febrile illness that can progress to a lethal encephalitis (Sejvar et al., JAMA. 290:511-530, 2003). Epidemiological documentations show that outbreaks of WNV fever and encephalitis have occurred in regions throughout the world in the Middle East, Europe, and Africa, the United States, Mexico, South America, and the Caribbean (Dauphin et al., Comp Immunol Microbiol Infect Dis. 27:343-355, 2004; Komar and Clark. Rev. Panam. Salud Publica. 19:112-117, 2006; Lanciotti et al., Science 286:2333-2337, 1999). Although vaccines are available for animal use, no vaccines or specific therapies for WNV are currently approved for humans. Nucleic acid and protein sequences of are available in public databases, including GenBank Accession Nos.: AY646354, JN183893, AF202541, KF234080, JF95718, and JQ928174, all of which are incorporated by reference as included in GenBank on Apr. 27, 2015. One of skill in the art can identify additional WNV sequences.

Yellow Fever Virus (YFV): Yellow fever is a vector-borne disease affecting humans and non-human primates in tropical areas of Africa and South America and is caused by the yellow fever virus (YFV) (Monath. Lancet Infect Dis 0.1:11-20, 2001). YFV which belongs to the family Flaviviridae. Infection with YFV is characterized by symptoms ranging from mild to hemorrhagic syndrome that can potentially lead to organ failure and fatal outcome. YFV sequences include GenBank Accession Nos.: AY640589, AY603338, and AY572535 which are incorporated by reference as included in GenBank on Apr. 27, 2015. Additional YFV species sequences can be identified by one skilled in the art.

Zika virus (ZKV): Zika virus disease (Zika) is a disease caused by the Zika virus, which is transmitted primarily through the bite of an infected Aedes species mosquito. The most common symptoms of ZKV are fever, rash, joint pain, and conjunctivitis (red/pink eyes) (Faye et al., PLoS Negl Trop Dis 8(1): e2636, 2014, doi:10.1371/journal.pntd.0002636). The illness is usually mild with symptoms lasting for several days to a week after being bitten by an infected mosquito. ZKV infection during pregnancy can cause a serious birth defect called microcephaly. Zika virus belongs to the family Flaviviridae (Lanciotti et al., Yap State, Micronesia, 2007). It was first discovered in 1947 and named after the Zika Forest in Uganda. In 1952, the first human cases of Zika were detected and since then, outbreaks of Zika have been reported in tropical Africa, Southeast Asia, and the Pacific Islands. ZKV sequences include GenBank Accession Nos.: EU545988, KJ776791, and AY632535 which are incorporated by reference as included in GenBank on Apr. 27, 2016. Additional ZKV species sequences can be identified by one skilled in the art.

III. Methods of Detecting Bacterial, Viral, and Protozoan Nucleic Acids

Herein disclosed are methods for detecting bacterial, viral, and protozoan nucleic acids in a biological sample such as those from individuals clinically suspected of being infected with said pathogens. The disclosed methods include real-time, quantitative (RT)-LAMP assays in which amplification reaction-components are shuffled and multiplexed for detection and identification of nucleic acids of pathogens (and their genotypes, subtypes or serotypes) including HIV, EBOV, MARV, HBV, HCV, CHIKV, MERS CoV, PAB19, CMV, JEV, MTB, HEV, DENV, SARS CoV, YFV, LFV, LE, TRY, ZKV and/or PLM. In some examples, the methods include real-time multiplex detection, quantitation, and differentiation of the genotypes of HCV in a sample and/or discriminating HCV-1 subtypes (such as HCV-1a, 1b, or 1c), HCV2 or HCV2 subtypes (such as HCV-2a, 2b, 2a/c, or 2c), HCV3 or HCV 3 subtypes (such as HCV-3a or 3b), HCV4 or HCV4 subtypes (such as HCV-4a, 4b, 4c, or 4d), HCV5 or HCV5 subtypes (such as HCV-5a), HCV-6 or HCV6 subtypes (such as HCV-6a or 6b) and HCV7. In other example, the method includes real-time multiplex isothermal detection, differentiation, and quantitation of HBV genotypes (for example detecting and/or discriminating HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, or HBV-F). In other examples, the methods include real-time isothermal multiplex detection, differentiation, and quantitation of EBOV in a sample and/or discriminating EBOV genotypes, (such as ZEBOV, SUDV, RESTV, TAFV, and BDBV). In further examples, the methods include real-time isothermal multiplex detection, differentiation, and quantitation of HEV (such as HEV-1, 2, 3, and 4) in a sample. In other examples, the methods include real-time isothermal multiplex detection, differentiation, and quantitation of HIV in a sample (such as HIV-1 and HIV-2). In another example, the methods include real-time isothermal multiplex detection, differentiation, and quantitation of Plasmodium species (such as Plasmodium falciparum, ovale, vivax, and malariae). In further examples, the methods include real-time isothermal multiplex detection, differentiation, and quantitation of Leishmania species (e.g. such as Leishmania donovani, braziliensis, tropica, major, and infantum). In further examples, the methods include real-time isothermal multiplex detection, differentiation, and quantitation of Trypanosoma species (e.g. such as cruzi, gambiense, and brucei rhodesiense). In another example, the methods include real-time isothermal multiplex detection, differentiation, and quantitation of Mycobacterium species (such as M. tuberculosis, M. avium, M. bovis, and M. lepra). In further examples, the methods real time isothermal detection, quantitation, and identification include detecting CHIKV, MERS CoV, SARS CoV, PAB19, CMV, JEV, WNV, YFV, LFV, ZKV and MARV in a sample or detecting DENV in a sample (for example detecting and/or discriminating DEN-1, 2, 3, or 4). Primers and probes for use in the disclosed methods are provided herein.

The methods herein described may be used for any purpose for which real-time isothermal multiplex detection, differentiation, and quantitation of bacterial, viral, and protozoan nucleic acids of HIV, EBOV, MARV, HBV, HCV, CHIKV, MERS CoV, SARS CoV, PAB19, CMV, JEV, TB, HEV, DENV, YFV, LFV, LE, TRY, ZKV and/or PLM is needed in a field, laboratory, or clinical setting for diagnostic and prognostic applications. The nucleic acids are isolated from appropriate clinical biological samples including, but not limited to, cells, tissues, blood, serum, plasma, urine, cerebrospinal fluid, nasopharyngeal aspirates, middle ear fluids, bronchoalveolar lavage, tracheal aspirates, sputum, vomitus, buccal swabs, vaginal swabs, stool, and rectal swabs. The samples can be directly used in amplification reaction. In further example, the samples are first treated with lysis buffer or heat-treated before application in reaction medium. In some examples, nucleic acids are isolated or extracted from the samples with various nucleic acid extraction methods known to one of skill in the art.

The disclosed methods are highly sensitive and specific for real-time isothermal multiplex detection, differentiation, and quantitation of nucleic acids of HIV, EBOV, MARV, HBV, HCV, CHIKV, MERS CoV, SARS CoV, PAB19, CMV, JEV, MTB, HEV, DENV, YFV, LFV, LE, TRY, ZKV, and/or PLM nucleic acids. In some examples, the disclosed methods can detect presence of at least about 1 International Unit (IU equivalent to about 5 copies) of HBV, HIV, or HCV nucleic acids (e.g. at least about 10 to 10⁵ or more IU of HBV, CHIKV, or HCV nucleic acids) in a sample or reaction volume. In other examples, the disclosed methods can detect presence of at least about 1 copy of HBV, HCV, HIV, WNV, EBOV, MARV, HBV, CHIKV, MERS CoV, SARS CoV, PAB19, CMV, JEV, TB, HEV, DENV, YFV, LFV, LE, TRY, ZKV and/or PLM nucleic acids (e.g. at least about 10 to 10⁶ or more copies) in a sample or reaction volume. In some examples, the disclosed methods can predict with a sensitivity of at least 80% and a specificity of at least 80% for presence of one or more of HBV, HCV, HIV, WNV, EBOV, MARV, HBV, CHIKV, MERS CoV, SARS CoV, PAB19, CMV, JEV, MTB, HEV, DENV, YFV, LFV, LE, TRY, ZKV and/or PLM nucleic acids in a sample, such as a sensitivity of at least 85%, 90%, 95%, or even 100% and a specificity of at least of at least 85%, 90%, 95%, or even 100%.

In some embodiments, the methods for detecting parasitic, viral and/or bacterial nucleic acids in a sample utilizing LAMP or RT-LAMP methods of amplification and detection. LAMP is a rapid, specific, and sensitive one-step isothermal amplification method that can produce amplified nucleic acids in a short period of time using a DNA polymerase with strand displacement activity (see e.g., Notomi et al., Nucl. Acids Res. 28:e63, 2000). LAMP can also be used for amplification of RNA targets by addition of reverse transcriptase (RT) in a one-step reaction utilizing one temperature, hence referred to as RT-LAMP. (RT)-LAMP can also be multiplexed and performed in real-time by the addition of multiple pathogen-specific or species-specific LAMP primer sets, and pathogen-specific or species-specific fluorooligonucleotides in a single reaction medium. This capability is advantageous, for example, because it allows for incorporation of internal control(s), amplification of six or more regions within the same target, or simultaneous detection of about two, three or more targets or pathogens in a single reaction. In some examples, the disclosed methods include a real-time quantitative, multiplex (RT)-LAMP assay for detection, quantitation, and/or discrimination for example of two or more of HIV, HBV, WNV, PLM, CMV, DENV, TRY, and LE in a single reaction and provision of pathogen load.

In some examples multiple pathogen-specific and/or gene-specific oligonucleotides and novel fluorooligonucleotides sets of (RT)-LAMP primers are mixed at concentrations ranging from 0.1-1.5 μM and added to a reaction master-mix containing 2.5-10 μL of the “Lysis Reaction Buffer” (LRB) Buffer. Thermostable enzymes [about 100 to 120 Units of Maloney Murine Leukemia Virus (MMLV), about 4 to 6 Units of Avian Myeloblastisis Virus (AMV) or other reverse-transcriptase] and about 6 to 12 Units of Bst DNA polymerase or other strand-displacement enzymes (e.g. such as Bst 2.0 DNA polymerase, Bst 2.0 WarmStart™ DNA polymerase (New England Biolabs, Ipswich, Mass.), Taq DNA polymerase, VentR® and Deep VentR® DNA polymerases (New England Biolabs), Klenow fragment of DNA polymerase I), and 2 to 6 Units of RNAse Inhibitor) are also added. The template (extracted nucleic acid, lysis buffer treated and/or heat-treated specimen) is added to 10-25 μL the total reaction volume. The appropriate internal, negative, and positive controls are also included. The tubes containing the mixtures are then subjected to a one-step, closed-tube amplification procedure, using a single incubation temperature between 40 to 75° C. for about 10 to 40 minutes, on a real-time portable multichannel heat device. In other examples (such as for RNA targets of HIV, HCV, EBOV, or SARS CoV), the reaction is conducted as a one-step, close-tube procedure without an extra complementary DNA synthesis step.

In some embodiments, the target nucleic acid is DNA (such as an HBV, CMV, Plasmodium or Mycobacterium nucleic acid). In some examples the amplification process is monitored live, observed, and acquired in real-time from/by a real-time multichannel fluorospectrometric detector in the closed-tube, one-step, and one-temperature procedure. The results are acquired in real-time by monitoring or reading the different amplification curves, dissociation or melt curves (as illustrated below in FIGS. 9 and 10), which emerge from different emission wavelengths (λ 300-800) at defined temperatures, thereby indicating detection and simultaneous diagnostic differentiation. In further examples, utilizing special electronic applications, the detection, identification, and quantitative pathogen load or gene expression information is transmitted in real-time via blue-tooth, WiFi, or other wireless electronic means to the cloud, a smart phone or tablet and simultaneously monitored in real-time by a doctor, field investigator, or lab technician irrespective of location. Agarose gel (at about 2-3%) electrophoresis is not required, but optional. Reaction tubes can also be visualized with the naked-eye to view fluorescence glow of amplified nucleic acid which is also not required, but optional.

In some examples, the isothermal reaction is conducted using a mixture including a suitable buffer (e.g. a phosphate or Tris buffer). The buffer may also include additional components, such as NaCl, KCl, MgCl₂, (NH₄)₂SO₄, MgSO₄, and/or Triton-X100 or Tween-20. The buffer may also include other additives such as 1-proline, betaine or dimethylsulfoxide. The mixture may also contain nucleotides or nucleotide analogs such dATP, dCTP, dGTP, and dTTP. In one example, the buffer is Lysis Reaction Buffer (LRB), described in Section V may be used. In other examples, the buffer is Loopamp reaction mix (Eiken Chemical Co., Ltd., Tochigi, Japan) or another commercially available polymerase or RT reaction buffer. One of skill in the art can select an appropriate buffer and any additives using routine methods.

Reading of Results

In some examples, the disclosed methods include detecting fluorescence from a detectable label or probe incorporated in one or more (RT)-LAMP primers (such as LF, LR, F3, and R3, FIP, and RIP) as described in FIG. 14. In some examples, the sample is identified as containing a bacterial, viral, or parasite nucleic acid (for example is “positive” for the virus) if an increase in fluorescence is detected compared to a control (such as a no-template control sample or a known negative sample). In other examples, the amount of viral nucleic acid in a sample is determined quantitatively with a real-time multichannel fluorospectrophotometeric heating system, whereby the amount of viral nucleic acid in a test sample can be determined and calculated in real time by comparing to the amount of fluorescence obtained in pre-quantitated standard samples or amounts of nucleic acid of interest.

Primers

In particular embodiment, the hybridization chemistry and amplification mechanism of the detection assay of this invention utilize (RT)-LAMP primers or oligonucleotides (Loop Forward—LF, Loop Reverse—LR, Forward Outer—F3, Forward Inner Primer—FIP, Reverse Outer—R3 or Reverse Inner Primer—RIP) of any of the SEQ ID Nos 1-306 designed as single-stranded bi-labeled fluorescent probes that are held in a hairpin-loop conformation by complementary stem sequences of about 4-7 nucleotides at both ends of the probes. The 3′-end of the designated oligonucleotide is tagged with any reporter (e.g. FAM, TET, Texas-Red, etc.), while the 5′-end contains a quencher molecule (e.g. BHQ1, BHQ2, BHQ3, DABCYL, etc.) or vice versa; the main loop is a single-stranded DNA sequence of about 15-44 nucleotides that is either complementary or reverse complementary to the target gene sequence of the pathogens (FIG. 14). These probes are more stable, more specific and sensitive and are well preserved during the course of the reaction.

A. Real Time Multiplex Assays

In a particular example, a real-time quantitative multiplex (RT)-LAMP reaction comprises contacting a sample with two or more primers and probes, wherein a set of HCV (RT)-LAMP primers/probes (such as selected from SEQ ID NOs: 1-68), a set of HBV LAMP primers/probes (such as selected from SEQ ID NOs: 69-86), a set of HEV LAMP primers/probes (such as primers/probes selected from SEQ ID NOs: 87-100), a set of HIV (RT)-LAMP primers/probes (such as selected from SEQ ID NOs: 101-112), a set of WNV (RT)-LAMP primers/probes (such as a set of LAMP primers/probes selected from SEQ ID NOs: 113-118), a set of DENV (RT)-LAMP primers/probes (such as selected from SEQ ID NOs: 119-130), a set of CHIKV LAMP primers/probes (such as primers/probes selected from SEQ ID NOs: 131-143), a set of CMV LAMP primers/probes (such as selected from SEQ ID NOs: 144-150), a set of PLM LAMP primers/probes (such as SEQ ID NOs: 151-156), a set of EBOV (RT)-LAMP primers/probes (such as selected from SEQ ID NOs: 157-169), a set of MARV (RT)-LAMP primers/probes (such as SEQ ID NOs: 170-175), a set of YFV (RT)-LAMP primers/probes (such as primers/probes selected from SEQ ID NOs: 176-181), a set of LE LAMP primers/probes (such as SEQ ID NOs: 182-187), a set of LFV LAMP primers/probes (such as SEQ ID NOs: 188-209), a set of MTB LAMP primers/probes (such as selected SEQ ID NOs: 210-221), a set of MERS CoV (RT)-LAMP primers/probes (such as selected from SEQ ID NOs: 222-234), a set of PAB19 LAMP primers/probes (such as a set of LAMP primers/probes selected from SEQ ID NOs: 235-246), a set of JEV (RT)-LAMP primers/probes (such as primers/probes selected from SEQ ID NOs: 247-258), a set of SARS CoV (RT)-LAMP primers/probes (such as a set of LAMP primers/probes selected from SEQ ID NOs: 259-276), a set of TRY LAMP primers/probes (such as SEQ ID NOs: 277-294), and a set of ZKV (RT)-LAMP primers/probes (such as primers/probes selected from SEQ ID NOs: 295-306), under conditions optimal for simultaneous amplification of two or more HBV, HCV, HIV, WNV, EBOV, MARV, HBV, CHIKV, MERS CoV, SARS CoV, PAB19, CMV, JEV, MTB, HEV, DENV, YFV, LFV, LE, TRY, ZKV and/or PLM nucleic acid.

In another embodiment, the real-time quantitative isothermal multiplex methods comprises contacting the sample with at least one FIP, RIP, F3, R3, LR or LF primer that includes a fluorophore and a quencher (herein referred to in some examples as a “fluorooligonucleotide or fluoro-oligo”). In some examples, the multiplex set of primers include two, three or more pathogen or species-specific fluorooligonucleotides tagged with different fluorophores and quenchers each for one or more of the bacterial, viral, or protozoan nucleic acids that can be detected by the assay. This enables closed-tube, one-tube simultaneous detection and identification of multiple bacterial, viral, and protozoan nucleic acids present in the sample by fluorescence emission from each pathogen-specific fluoro-oligo. Relative to an internal quantitated assay positive control, an increase in fluorescence over background, no-template control, and/or a known negative control sample reaction would indicate the presence of the nucleic acid of particular pathogen(s) in the sample. In further example, the real-time quantitative multiplex set of primers which include one or more pathogen-specific or species-specific fluorooligonucleotide tagged with different fluorophores and quenchers can be shuffled and rearranged to target an intended group of pathogens (e.g. EBOV, PLM, and YFV or DENV, JEV, WNV, and LFV, among others).

IV. Lysis Buffer

Disclosed herein is a novel lysis buffer formulation that can be used for lysis of pathogen contained in blood product (e.g. plasma and serum). In some embodiment, the buffer is approximately of pH 7.8 and contains the following ingredients: about 5-20 mM Tris-HCl, 1-5 mM EDTA, 5-20% Sucrose, 0.1-0.4% Triton X-100, and 0.01-0.05% Tween-20 (see FIG. 13).

V. Assay Lysis-Reaction Buffer

Disclosed herein is a novel assay lysis-reaction buffer that can be used for nucleic acid detection. This novel buffer/solution was formulated to simultaneously perform lysis and amplification (the Lysis-Reaction Buffer—LRB is about pH 7.6 to 8.0 and of various stock concentrations). The buffer can be stored at room temperature, with no refrigeration required. The LRB comprises: 0.1-0.4% Triton-X 100; 10-20% Sucrose; 0.1-1M Trehalose; 5-40 mM Tris-HCl; 5-20 mM KCl; 5-20 mM (NH₄)₂SO4; 5-12 mM MgSO₄; 1-3.0 mM each dNTPs; 1-5 mM Tris-Acetate; and 5-12 mM Potassium-Acetate. The LRB can be used to perform isothermal amplification, regular PCR or qRT-PCR, and complementary DNA synthesis. In some examples the buffer performs lysis of viral cells (from blood, plasma, and serum sample that are added to the reaction) and simultaneously amplified the released DNA or RNA, less nucleic acid extraction (see FIGS. 11 and 12). The LRB contains a combination of sucrose and trehalose which is a non-reducing disaccharide that confers stability as well as tolerance to heat and oxidation, increases enzymatic activities, and enhances priming specificity in differential real-time multiplex isothermal amplification reaction (see FIGS. 9 and 10). The LRB is highly stable at varying temperatures ranging from about 25° C. to 65° C. or higher and is stable for protracted periods of at least 12 months or more at room temperature. In a particular example, the LRB (containing at least about 12 Units of Bst DNA polymerase, ˜6 Units of cloned AMV reverse-transcriptase, and about 4 Units of an RNase inhibitor) was heat-stressed at temperatures up to about 65° C. over a 5 to 7-day period, lyophilized and stored at room temperature for up to about 12 months or more. In other example, the lyophilized LRB (including enzymes) maintained an extreme stability, re-constituted/re-suspended with appropriate solutions (e.g. nuclease-free H₂O) and successfully utilized in (RT)-LAMP, PCR, and RT-PCR for synthesis and amplification of nucleic acid, hence demonstrating advantages over conventional or commercially available reaction buffers.

V. Primers, Probes, and Kits

Disclosed herein are primers and probes suitable for real-time quantitative isothermal multiplex detection, quantitation, and identification of bacterial, viral, and parasitic nucleic acids (such as HBV, HCV, HIV, WNV, EBOV, MARV, HBV, CHIKV, MERS CoV, SARS CoV, PAB19, CMV, JEV, MTB, HEV, DENV, YFV, LFV, LE, TRY, ZKV and/or PLM nucleic acids using real-time quantitative multiplex (RT)-LAMP.

In some embodiments, the disclosed primers and/or probes are about 10 to 60 nucleotides in length and are capable of hybridizing to, and in some examples, amplifying the disclosed nucleic acid molecules.

In other embodiments, the primers herein disclosed include (RT)-LAMP primers for real-time isothermal amplification of HCV nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 1-68 (which for example includes HCV universal primers). In further examples, the primers include (RT)-LAMP primers for real-time quantitative isothermal amplification of specific HCV genotypes and subtypes, such as primers with at least 90 to 99% sequence identity to SEQ ID NOs 1-68 (HCV-1, HCV-2, HCV-3, HCV-4, HCV-5, and/or HCV-6).

In another embodiments, the primers herein disclosed include (RT)-LAMP primers for real-time isothermal amplification of HBV nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 69-86 (which for example, includes HBV universal primers). In some examples, the primers include (RT)-LAMP primers for real-time quantitative amplification of nucleic acids of HBV genotypes, such as primers that consists of or having least 90 to 99% sequence identity to SEQ ID NOs 69-86 for real-time quantitative amplification of HBV nucleic acids (for example HBV-A, HBV-B, HBV-C, HBV-D, HBV-E, and/or HBV-F).

In further embodiments, the disclosed primers include (RT)-LAMP primers for real-time quantitative isothermal amplification of HEV nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 87-100. In some examples, the primers have at least 95 to 99% sequence identity to any one of SEQ ID NOs 87-100, comprise the sequence of any one of SEQ ID NOs 87-100, or consist of the sequence of any one of SEQ ID NOs 87-100 for amplification of HEV genotypes.

In additional embodiments, the primers herein disclosed include (RT)-LAMP primers for real-time isothermal quantitative amplification of HIV nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 101-112. In some examples, the disclosed HIV primers are capable of amplifying nucleic acids from HIV-1 and HIV-2. In some examples, the primers have at least 95 to 99% sequence identity to any one of SEQ ID NOs 101-112, comprise the sequence of any one of SEQ ID NOs 101-112, or consist of the sequence of any one of SEQ ID NOs 101-112.

In further embodiments, this disclosure include (RT)-LAMP primers for real-time quantitative isothermal amplification of WNV nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 113-118. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs 113-118, comprise the sequence of any one of SEQ ID NOs 113-118, or consist of the sequence of any one of SEQ ID NOs 113-118.

In still further embodiments, the disclosed primers include (RT)-LAMP primers for real-time quantitative isothermal amplification of DENV nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 119-130. In some examples, the primers are capable of amplifying nucleic acids from one or more DENV serotypes (for example, one or more of DENV-1, DENV-2, DENV-3, and/or DENV-4), such as SEQ ID NOs 119-130. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs: 62-75, comprise the sequence of any one of SEQ ID NOs 119-130, or consist of the sequence of any one of SEQ ID NOs 119-130. In particular examples, the primers amplify a DENV-1, DENV-2 DENV-3, and/or DENV-4 nucleic acid in real-time.

In further embodiments, this disclosure includes (RT)-LAMP primers for real-time quantitative isothermal amplification of CHIKV nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 131-143. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs 131-143, comprise the sequence of any one of SEQ ID NOs 131-143, or consist of the sequence of any one of SEQ ID NOs 131-143.

In another embodiments, this disclosure includes LAMP primers for real-time quantitative isothermal amplification of CMV nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 144-150. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs 144-150, comprise the sequence of any one of SEQ ID NOs 144-150, or consist of the sequence of any one of SEQ ID NOs 144-150.

In still further embodiments, the disclosed primers include (RT)-LAMP primers for real-time quantitative isothermal amplification of PLM nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 151-156. In some examples, the primers are capable of amplifying nucleic acids from one or more PLM species (for example, one or more of PLM-falciparum,PLM-ovale,PLM-vivax, and/or PLM-malariae), such as SEQ ID NOs 151-156. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs 62-75, comprise the sequence of any one of SEQ ID NOs 151-156, or consist of the sequence of any one of SEQ ID NOs 151-156. In particular examples, the primers can amplify a PLM-falciparum, PLM-ovale, PLM-vivax, and/or PLM-malariae nucleic acid in real-time.

In further embodiments, the disclosed primers include (RT)-LAMP primers for real-time quantitative isothermal amplification of EBOV nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 157-169. In some examples, the primers are capable of amplifying nucleic acids from one or more EBOV species (for example, one or more of ZEBOV, SUDV, TAFV, RESTV, and BDBV), such as SEQ ID NOs 157-169. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs 62-75, comprise the sequence of any one of SEQ ID NOs 157-169, or consist of the sequence of any one of SEQ ID NOs 157-169. In particular examples, the primers can amplify a ZEBOV, SUDV, TAFV, RESTV, and BDBV nucleic acid in real-time.

In additional embodiments, this disclosure includes (RT)-LAMP primers for real-time quantitative isothermal amplification of MARV nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 170-175. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs 170-175, comprise the sequence of any one of SEQ ID NOs 170-175, or consist of the sequence of any one of SEQ ID NOs 170-175.

In further embodiments, this disclosure includes (RT)-LAMP primers for real-time quantitative amplification of YFV nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 176-181. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs 176-181, comprise the sequence of any one of SEQ ID NOs 176-181, or consist of the sequence of any one of SEQ ID NOs 176-181.

In yet further embodiments, this disclosure includes (RT)-LAMP primers for real-time quantitative isothermal amplification of LE nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 182-187. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs 182-187, comprise the sequence of any one of SEQ ID NOs 182-187, or consist of the sequence of any one of SEQ ID NOs 182-187.

In still further embodiments, this disclosure includes (RT)-LAMP primers for real-time quantitative isothermal amplification of LFV nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 188-209. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs: 188-209, comprise the sequence of any one of SEQ ID NOs 188-209, or consist of the sequence of any one of SEQ ID NOs 188-209.

In additional embodiments, this disclosure includes (RT)-LAMP primers for real-time quantitative isothermal amplification of MTB nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 210-221. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs 210-221, comprise the sequence of any one of SEQ ID NOs 210-221, or consist of the sequence of any one of SEQ ID NOs 210-221.

In another embodiments, this disclosure includes (RT)-LAMP primers for real-time quantitative isothermal amplification of MERS CoV nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 222-235. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs 222-235, comprise the sequence of any one of SEQ ID NOs 222-235, or consist of the sequence of any one of SEQ ID NOs 222-235.

In further embodiments, this disclosure includes (RT)-LAMP primers for real-time quantitative isothermal amplification of PAB19 nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 236-246. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs 236-246, comprise the sequence of any one of SEQ ID NOs 236-246, or consist of the sequence of any one of SEQ ID NOs 236-246.

In still further embodiments, this disclosure includes (RT)-LAMP primers for real-time quantitative isothermal amplification of JEV nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 247-258. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs 247-258, comprise the sequence of any one of SEQ ID NOs 247-258, or consist of the sequence of any one of SEQ ID NOs 247-258.

In further embodiments, this disclosure includes (RT)-LAMP primers for real-time quantitative isothermal amplification of SARS CoV nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 259-276. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs 259-276, comprise the sequence of any one of SEQ ID NOs 259-276, or consist of the sequence of any one of SEQ ID NOs 259-276.

In further embodiments, this disclosure includes (RT)-LAMP primers for real-time quantitative isothermal amplification of TRY nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 277-294. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs 277-294, comprise the sequence of any one of SEQ ID NOs 247-258, or consist of the sequence of any one of SEQ ID NOs 277-294.

In still further embodiments, this disclosure includes (RT)-LAMP primers for real-time quantitative isothermal amplification of ZKV nucleic acids, including primers with at least 90% sequence identity to any one of SEQ ID NOs 295-306. In some examples, the primers have at least 95-99% sequence identity to any one of SEQ ID NOs 295-306, comprise the sequence of any one of SEQ ID NOs 295-306, or consist of the sequence of any one of SEQ ID NOs 295-306.

In some examples, at least one of the disclosed primers includes a detectable label, such as a fluorophore. In another examples, the F3, R3, FIP, RIP, LF, or LR primer (e.g., any one of SEQ ID NOs 1 to 306, specifically illustrated with SEQ NOs 1, 2, 5, and 6) includes a fluorophore at the 3′ end and a quencher at the 5′end or vice versa at the 5′ end and 3′ end. In further examples, the F3, R3, FIP, RIP, LF, and LR primer (e.g., any one of SEQ ID NOs: 1 to 306) includes fluorophores such as FAM, TET, Cy3, Cy5, Texas-Red-615 or other fluorophore deemed suitable. In still further examples, the F3, R3, FIP, RIP, LF, and LR primer (e.g., any one of SEQ ID NOs: 1 to 306) includes a quenchers such as DABCYL or a dark quencher, which is a Black Hole Quencher (such as BHQ1, BHQ2, BHQ3) or other available quenchers deemed suitable.

The present disclosure provides a novel (RT)-LAMP “Shufflex” probes designed of the F3, R3, FIP, RIP, LF, or LR of any of the SEQ ID Nos 1-306 as single-stranded bi-labeled loop fluorescent probes that are held in a hairpin-loop conformation by complementary stem-sequences at both 5′ and 3′ ends or 3′ and 5′ ends, wherein the complementary stem sequences of the probes is about 4 to 7 nucleotides to which a desirable fluorophore, reporter or quencher is conjugated. In further example, the hairpin-loop of the probe is a single-stranded DNA sequence of about 15 to 44 nucleotides that is complementary and/or reversely complementary to the target gene sequence of the target pathogens. In still further example, Shufflex (RT)-LAMP probes can have 90 to 99% identity to a nucleic acid including those sequences shown in SEQ ID Nos 1-306, are more specific, highly sensitive, and well preserved over the time course of the real-time multiplex amplification reaction.

The nucleic acid primers and probes herein disclosed can be supplied in the form of a kit for use in the real-time quantitative, multiplex isothermal amplification of two or more bacterial, viral, and parasite nucleic acids (such as two or more of HBV, HCV, HIV, WNV, EBOV, MARV, HBV, CHIKV, MERS CoV, SARS CoV, PAB19, CMV, JEV, MTB, HEV, DENV, YFV, LFV, LE, TRY, ZKV and/or PLM). In such a kit, an appropriate amount of two or more of the nucleic acid probes and/or primers (such as two or more F3, R3, FIP, RIP, LF, LR primers or Shufflex probes of SEQ ID NOs 1-306) is provided in one or more containers or in one or more individual wells such as a multi-well nano-microfluidic plate for real-time quantitative multiplex isothermal amplification, detection and identification of bacterial, viral, and parasitic nucleic acid as well as quantitation of the pathogen load. The nucleic acid probe and/or primer may be provided in the form of an aqueous solution or may be provided in a freeze-dried or lyophilized form contained in bottles, microfuge tubes or in a multi-well plate. In some examples, the kit will provide some amount of LRB, DNA polymerase, reverse-transcriptase, nuclease-free water and other reagents needed for additional use as may be suggested by an enclosed protocol manual or needed by individual end-user. In such a kit is provided three or more assay positive and negative controls bacterial, viral, or parasitic nucleic acid as plasmids or transcripts. However, one of skill in the art can select other suitable controls.

The present disclosure is illustrated by the following non-limiting Examples.

Example 1 Assay Reagents

Sets of primers were designed for real-time multiplex (RT)-LAMP assays for HBV, HCV, HIV, WNV, EBOV, MARV, HBV, CHIKV, MERS CoV, SARS CoV, PAB19, CMV, JEV, MTB, HEV, DENV, YFV, LFV, LE, ZKV, TRY, and/or PLM (see Table 1). Any of the F3, R3, FIP, RIP, LF, LR primer for each set may include a complementary stem-attached fluorophore and quencher at the 5′ and 3′ ends or at the 3′ and 5′ ends, respectively; wherein “F”=fluorophore, “Q”=quencher, and stem of complementary nucleotides (see FIG. 14).

TABLE 1 (RT)-LAMP nucleotide primer sequences Oligo SEQ ID Pathogen Name Oligonucleotide Sequence (5′-3′) NO. HCV N5F3 CATAGTGGTCTGCGGAACC 1 N5R3 CACGGTCTACGAGACCTCC 2 N5FIP CGGGCATTGAGCGGGTTTATCCTTTTGGTGAGT 3 ACACCGGAATTGC N5RIP CGCGAGACTGCTAGCCGAGTTTTTAGCACCCTA 4 TCAGGCAGTAC N5LF AAAGGACCCGGTCATCCC 5 N5LR GTCGCGAAAGGCCTTGTG 6 N6F3a TAGTGGTCTGCGGAACCG 7 N6R3a CACCGTCTACGAGACCTCC 8 N6FIPa GGCATTGAGCGGGTTTGATCCATTTTGAGTACA 9 CCGGAATTGCCA N6RIPa GCAAGACTGCTAGCCGAGTAGCTTTTCACTCGC 10 AAGCACCGTAT N6LFa AAAGGACCCGGTCGTCC 11 N6LRa GTTGGGTTGCGAAAGGCC 12 N6F3b CGGGAGAGCCATAGTGGT 13 N6R3b CACCGTCTACGAGACCTCC 14 N6FIPb TGAGCGGGTTTGATCCAATGGATTTTTGCGGAA 15 CCGGTGAGTAC N6RIPb CCGCAAGACTGCTAGCCGAGTTTTACCGTATCA 16 GGCAGTACCAC N6LFb TCGTCCTGGCAATTCCGG 17 N6LRb: TAGCGTTGGGTTGCGAAAG 18 N4F3b ACCGGGTCCTTTCTTGGATT 19 N4R3b: CGGTTGGTGTTACGTTTGGT 20 N4FIPb GACCCAACACTACTCGGCTAGCTTTTCGCTCAA 21 TGCCCGGAAAT N4RIPb GCCTTGCGGTACTGCCTGATTTTTGATTCGTGCT 22 CATGGTGCA TF3 CGGGAGAGCCATAGTGGT 23 TR3 CACGGTCTACGAGACCTCC 24 TFIP AGGCATTGAGCGGGTTTATCCATTTTTGCGGAA 25 CCGGTGAGTAC TRIP CCGCAAGACTGCTAGCCGAGTTTTACCCTATCA 26 GGCAGTACCAC TLF AAAGGACCCGGTCGTCC 27 TLR GTTGGGTCGCGAAAGGC 28 29 30 31 HCV 2F3 AATAGGGGCGACACTCCG 32 2R3 GTCTTCCCGGCAATTCCG 33 2FIP ACGCCATGGCTAGACGCTTTTTTTATGAACCAC 34 TCCCCTGTGA 2RIP TGAGTGTCGTACAGCCTCCAGGTTTTCGGTTCC 35 GCAGACCACTA 2LF GTACTCACCGGTTCCGCA 36 2LR CCCCCGCAAGACTGCTA 37 SF3 CCCCTGTGAGGAACTACTGT 38 SFIP ACTATGGCTCTCCCGGGAGGTTTTCGTCTAGCC 39 ATGGCGTTAG SRIP GGAACCGGTGAGTACACCGGTTTTCCCAAATC 40 TCCAGGCATTGA SLF AGGCTGCACGACACTCATA 41 SLR GACCGGGTCCTTTCTTGGA 42 2-F3-1 AGTGTCGTACAGCCTCCAG 43 2-R3-1 ACCCTATCAGGCAGTACCAC 44 2-FIP-1 ACCCAGTCTTCCCGGCAATTCTTTTCGGGAGAG 45 CCATAGTGGT 2-BIP-1 CCACTCTATGCCCGGCCATTTTTTCAACCCAAC 46 GCTACTCGG 2-LF-1 TGTACTCACCGGTTCCGCA 47 2-LR-1 TGCCCCCGCAAGACTGCTA 48 2-F3-2 CGGGAGAGCCATAGTGGT 49 2-R3-2 CACGGTCTACGAGACCTCC 50 2-FIP-2 AATGGCCGGGCATAGAGTGGTTTTGCGGAACC 51 GGTGAGTACA 2-RIP-2 CCGCAAGACTGCTAGCCGAGTTTTCACCCTATC 52 AGGCAGTACCA 2-LF-2 CCAGTCTTCCCGGCAATTCCG 53 2-LR-2 TAGCGTTGGGTTGCGAAAGGC 54 HCaF3 CCCCTGTGAGGAACTACTGT 55 HCaR3 CTCGGCTAGCAGTCTTGC 56 HCaFIP ACTATGGCTCTCCCGGGAGGTTTTCGTCTAGCC 57 ATGGCGTTAG HCaRIP GGTCTGCGGAACCGGTGAGTATTTTGACCGGA 58 CATAGAGTGGGT HCaLF GGAGGCTGTACGACACTCATA 59 HCaLR GGAATTCCCGGAAAGACTGGG 60 HCa2R3 CGT ACT CGC AAG CAC CCT ATC 61 62 HVC DF3-2n GCCATAGTGGTCTGCGGA 63 DR3-2n AAGCACCCTATCAGGCAG 64 DFIP-2n TATTGAGCGGGTTGCTCCAAGTTTTCCGTGAGT 65 ACACCGGAATC DRIP-2n CCAGAATTTGGGCGTGCCCTTTTACCACAAG 66 GCCTTTCGCGA DLF-2n AGGACCCGGTCACCCCAGC 67 DLR-2n CGCGAGATCACTAGCCGAGTAGTG 68 HBV HBF3 GAA CAT GGA GAA CAT CAC ATC A 69 HBR3 GAT AAA ACG CCG CAG ACA CAT C 70 HBFIP GGG TGA TCC CCC TAG AAA ATT G-TTTT-GAA 71 TCC TCA CAA TAC CGC AGA G HBRIP GTG TGT CTT GGC CAA AAT TCG C-TTTT-CAG 72 CGA TAA CCA GGA CAA ATT G HBLF AGA AGT CCA CCA CGA GTC TAG 73 HBLR TCA CTC ACC AAC CTC CTG TCC T 74 HBF3c AACATCACTACCAGCACGG 75 HBR3c ACCACTGAACAAATGGCACT 76 HBFIP3c TGCAGTTTCCGTCCGAAGGTTTTTTTTGCAAGA 77 CCTGCACGATTC HBRIP3c CCATCCCATCATCCTGGGCTTTTTTAGGAGAAA 78 CGGACTGAGGC HBLF3c AAACATAGAGGTTCCTTGAGCAG 79 HBLR3c TCGCAAGATTCCTATGGGAGT 80 HBF3n CATCACTACCAGCACGGGAC 81 HBR3n CCACTGAACAAATGGCACTAGT 82 HBFIP3n TGCAGTTTCCGTCCGAAGGTTTTTTTTGCAAGA 83 CCTGCACGATTC HBRIP3n CCATCCCATCATCCTGGGCTTTTTTCAGGAGAA 84 ACGGACTGAGGC HBLF3n GAAACATAGAGGTTCCTTGAGCAG 85 HBLR3n TCGCAAGATTCCTATGGGAGT 86 HEV HE1F3 GTTGCTGCTCCTCATGTTTTTGC 87 HE1R3 TGGCGAACACGAGGTCCAGC 88 HE1FIP ACCGCCGCTGCGCCGCCCAC-TTTT- 89 ATGCTGCCCGCGCCACCGCC HE1RIP GGCGGTGGTTTCTGGGGTGA-TTTT- 90 CGGCCGCAGCGGTGACATCG HE1LF CGGCGGCCAGACGGCTGAC 91 HE1LR GGTTGATTCTCAGCCCTTCG 92 HEV HE3-F3 GCCCTTCGCCCTCCCCTATATT 93 HE3-R3a AGGTACAGGGGCTGTGTCAG 94 HE3-R3b CAACATCAGGTACAGGGGCTG 95 HE3-R3b CAACATCAGGTACAGGGGCTG 96 HE3-FTP CGGCTGCCGAGGGCGAGTTCCA-TTTT- 97 GATTCTCAGCCCTTCGCCCTCC HE3-RIP GTGACCAGTCCCAGCGCCCCTC-TTTT- 98 GAGATAGCAGTCAACGGCGC HE3-LFc GAT TGT GAA ACG ACA TCG GC 99 HE3-LRc CTGCCCCAGCTGGGGCTGCGCC 100 HIV HI1F3 CAC CAT GCT AAA CAC AGT GG 101 HI1R3 TCC TGA AGG GTA CTA GTA GT 102 HI1FIP TCT GCA GCT TCC TCA TTG ATG G-TTTT- 103 CACAGTGG GGGGACATCA AGCA HI1RIP ATG GGA TAG ATT GCA TCC AGT G-TTTT-CTT 104 CCC CTT GGT TCTCTCATC T HI1LF TCT TTT AAC ATT TGC ATG GC 105 HI1LR CAT GCA GGG CCT ATT GCA CCA G 106 HI2F3 CAG GGA CTT TCC AGA AGG GGC 107 HI2R3 AGG TCT TTA AGC AAG CAA GCG 108 HI2FIP AAGCGGGTACATTTATACAG-TTTT- 109 CCAAGGGAGGGACATGGGAG HI2RIP TGCATTGTATTCAGTCGCT-TTTT-GCT CTA CCT 110 GCT AGT GCT HI2LF GGC GTT CCC CAC CAG CTC 111 HI2LR GCG GAG AGG CTG GCA GAT 112 WNV WNF3 GTT GGC TCT CTT GGC GTT CTT C 113 WNR3 TCA TAA GTG ATA GTA TCA TCG C 114 WNFIP AGC ACT GGT CAA GGT CCC TAG T -TTTT- 115 AGG TTC ACA GCA ATT GCT CC WNRIP CAGTCATG ATTGGCCTGA TCGC-TTTT-CAT 116 CAC CTT CCC TTG GAA GTT A WNLF CCT TCT TAA AAC TCA GAA GGT G 117 WNLR GCGT AGGAGCAGTT ACCCTCT 118 DENV D1F3 GCC ACG GTT TGA GCA AAC CGT G 119 D1R3 TTA TTG TTA TGC CGG GGG TCT C 120 D1FIP GCTACCCCATGCGTACAGCTTC-TTTT- 121 GCCTGTAGCTTCATCGTGGGGA D1RIP AGACTAGTGGTTAGAGGAGACC-TTTT- 122 CAGGATACAGCTTCCCCTGGTG D1LF CAT GGG TTG CAG CCT CCC AGG 123 D1LR AACATAACGCAGCAGCGGGG CC 124 DENV D2-F3 CAGGAGGAAGCTGGGTTGAC 125 D2-R3 ACCATGGAGTGTTTGCAGA 126 D2-FIP CTTCCATGTTCCAAGACTA-TTTT- 127 CTGGGTTGACATAGTCTTG D2-RIPa CTGTGTGACGACGATGGCG-TTTT- 128 GGCTTCTGTTTTTATCAG D2-RIPb CTGTGTGACGACGATGGCG-TTTT- 129 GTCAGCTTTGCCTCTATACA D2-LF CAGTTCAAAATCCAATGTTGG 130 CHIKV CKF3 GAC TCA ACC ATC CTG GAT ATC G 131 CKR3 GCG TCT CCG TGT CTG GCA CGG CC 132 CKR3a CTG TCT ACA TGA GAC GTC TGT G 133 CKFIP CTC TCG GGA TCT TCC GCA CTG C -TTTT- 134 CAGCAAGGAGGATGATGTCGGA CKRIP CTCGCCAATTATGCGAGAAAGC -TTTT-TAC 135 TGC TTG TAA GTC CCC GAT C CKLF GCAGACGCAGTGGTACTTCCTG 136 CKLR GCATCTGCCGCAGGAAAAGTCC 137 CV-F3 CCT GGA TAT CGG CAG TGC GC 138 CV-R3 GGC ACG GCC ATT ACT GCT TG 139 CV-FIP GGG ATC TTC CGC ACT GCG CA-TTTT-AGG 140 AGG ATG ATG TCG GAC AG CV-RIP TAT GCG AGA AAG CTA GCA TC-TTTT-CTT 141 TCC AGA GAT GTT TCT GT CV-LF GGG CAG ACG CAG TGG TAC TT 142 CV-LR TGC CGC AGG AAA AGT CCT GG 143 CMV CMF3 CCG ACA AGA AGA GGC CGG CG 144 CMR3 CGA TCT GTC GTA GTG CCC ACT G 145 CMFIP GGT GTT TGT GAG AGG CAG GTG A -TTTT-GCC 146 CTA GAC CGC CAG GCC GCA C CMRIP CGT GGA CCT GGC CAA ACG AGC CC-TTTT- 147 ATG TAG ACC AGG CGT ACG AGG C CMRIPa CGT GGA CCT GGC CAA ACG AGC CC -TTTTT- 148 AGA TGT TGC TGA TTC TGT TTA G CMLF CAT AAA TTC TTG TAT TTG TAA G 149 CMLR TCA CCG ACA TCA CCA GCC TCG T 150 PLM PFF3 GCT TCC TTC AGT ACC TTA TG 151 PFR3 GCA TCA CCA TCC AAG AAA TC 152 PFFIP TTC CGT CAA TTC TTT TAA CT-TTTT-ATC AAA 153 GTC TTT GGG TTC TG PFRIP GGG CAC CAC CAG GCG TGG AG-TTTT-TCT 154 TGT CTT AAA CTA GTG AG PFLF TCG CTT GCG CGA ATA CTC 155 PFLR GCG GCT TAA TTT GAC TCA AC 156 EBOV EZgF3 CCA CAA GAT CTT GAC AGC AG 157 EZgR3 CCG CAC TCT CTT GAA AAT CAA C 158 EZgR GCA TGA GAA GGA AAC TGT CCG C 159 EZgFIP ACT TGA TAC ACT GGG ATG A-TTTT-GTC TGT 160 CCG TTC AAC AGG EZgRIP ACA ATC TTG AGG AAA TTT GC-TTTT-ACT 161 CTC TTG AAA ATC AAC AC EZgLF CTC TTT GCC GAA CAA TCC 162 EZgLR CAA CTT ATC ATA CAG GCC TTT G 163 EBZ-F3 GCATCAAGCATCATGGCACC 164 EBZ-R3 CTG ACA TGC ATA TAA CAC TGT G 165 EBZ-FIP TAC CTA AAT GCA AGA TTG TA-TTTT-CAT 166 GCC ACA GTT AGA GGG AG EBZ-RIP GAGTTTACAGCACCTTTTAT-TTTT-TTA AAA 167 ACA TTC TTA ACA CC EBZ-LF TCT CTA AAT CAG TTA CAA AGC 168 EBZ-LR GAA TAT TGC AAC CGT TGC TA 169 MARV MBVF3 GAC ACA CAA AAA CAA GAG ATG 170 MBVR3 TCC CTG AGT TTA TTG CAT CTA T 171 MBVFIP GGG GCT GTG GGT TTT GTA CC-TTTT-ATG 172 ATT TTG TGT ATC ATA TAA A MBVRIP CAT GTT CGT AAT AAG AAG GTG AT-TTTT- 173 TTA CAG ATA CTA ACC TGA TG MVBLF AAT GTC AAT GTT AAT ATT CTT C 174 MBVLR GCC CCT CAT GTT CGT AAT AAG A 175 YFV YF2F3 CAG AGA TGG AGA CTC ATA CTA C 176 YF2R3 ACA ATT CCT CAC TAG TTC TCT G 177 YF2FIP CAC CTC CAT GTT GTC CAA GAG C-TTTT- 178 CAAGTGAAGATAATGCCCACCA YF2RIP GCC CCA CTC TAT GGC GTT GAA G-TTTT-TCC 179 TCT GGT CAT CCC TCA GTC T YF2LF GAG GCC TCC AAC CAG CAG AC 180 YF2LR CAC CAG TTT CCC CTG GTG AAA T 181 LE LEF3 CAC GCG AAA GCT TTG AGG TTA CA 182 LER3 GCT TGG ATC TCG TCC GTT GAC GG 183 LEFIP ATT AAA CCG CAC GCT CCA CGT C-TTTT-GTC 184 TCA GGG GGG AGT ACG TTC G LERIP GTA AAG TTC CCC GTG TTG AGT C-TTTT-TGC 185 ACC ACC ATT CAG GGA ATC G LELF GTG GTG CCA TTC CGT CAA TTT C 186 LELR ATC CTC ATC CTG TCC GGA TCT G 187 LFV LA1F3 GAG GCT GAA CTA AAA TGC TTC 188 LA1R3 AAT GCT CAT TTG TGC TTC AGC T 189 LA1FIP TTG AAG TCA AAC AGC CTC AGC A -TTTT- 200 GAACACAGCTGTGGCAAAATGT LA1RIP AAC AAG CCA TTC AAA GGC TGA A-TTTT-AAT 201 GCT CAT TTG TGC TTC AGC T LA1LF TGT CAC AAA ATT CCT CAT CAT G 202 LA1LR AGCTGAAGCACAAATGAGCATT 203 LA2F3 TTC CGG GGG AGT GCA TCA AT 204 LA2R3 GCA ACT TGA CCC AAA TGC TAA G 205 LA2FIP AAG CAG GAT GCT AAG TAC TCA C -TTTT- 206 CAG CAC TGG TCA AGC CCG GTT G LA2RIP AAT CAG TAG GTT CAC GGA AGA A -TTTT- 207 TGA AGG AAG ACC TGA AGA TC LA2LF TTG ATG TCA CAG ACC TCT TCG C 208 LA2LR AAG TTC AGG CTG CTA CAT ACA C 209 MTB TB1F3 CGGTTCAGGCTTCACCACAGTG 210 TB1R3 GAGTTGGATCTGATGTCCGAGT 211 TB1FIP ATTGAGCCAAGCCCTTTGCTGA-TTTT- 212 CGGCGACCCTAAGGTTGACGAC TB1RIP CGTCCAGCCATTGACCATCGTC-TTTT- 213 GCGCTCGATTTCGTTTTGGACA TB1LF CGCTGAGATTAGCATCACTGCT 214 TB1LR GCTCTGTTATCCGTGCCGAGCA 215 TB2F3 TCACGACAGATTGCGATGTACC 216 TB2R3 AGAACGTTGTCGGAAGAACACGC 217 TB2FIP ATCTTGCGTTGGGCGTACATGA-TTTT-CGTGAG 218 CTCACCGATCTTTCGT TB2RIP CTGTCCGAGATGGCCGAGCGCC-TTTT-AGCGCT 219 TGGAGCGCTGACGGAT TB2LF GGTTGTGTGATCACGGCCGAAC 220 TB2LR GTGAGGTCTTTGATCACGTCAA 221 MERS CoV ME1F3 CAAGGTGCGCGCGGTACGTA 222 ME1R3 GCAATGAGCCTCTCAACCAG 223 ME1FIP TTCCTGAACCACAGAGTGGC-TTTT- 224 GAGCAGCGCTCAACTCTGAA ME1RIP GCCTATGAAGTGGTGAAGGC-TTTT- 225 GGAGGTGTCTAGTGTGTCCA ME1LF GTTAGAGACACATGGTCTTG 226 ME1LR CTATGTGCCCATCCGGCTGG 227 MERS CoV ME2F3 CGTTGTCAACGATGTTGTCCT 228 ME2R3 CACCTAAGCCAGTGAGAACTAC 229 ME2R3a ACAGAGTTGCAAACCTTGTACG 230 ME2FIP CACGCAACTTGTCAAGGGTG-TTTT- 231 CGCAATTCTCTCTGGAACCA ME2RIP CGTAGCAGTCACTGCCGGCC-TTTT- 232 TAATGGCGGCATACTGTAATC ME2LF CACCTTTGAGAAGCTGGCGTA 233 ME2LR GCTATTAATGTTGGTGGTACAG 234 PAB19 PV1F3 AGTTATCTGACCACCCCCATGCC 235 PV1R3 GGATTTATTCCCAACTTAGCCA 236 PV1FIP CCCAACATAGTTAGTACCGGGT-TTTT- 237 TGCAGTATTATCTAGTGAAGAC PV1RIP ACCCGGTACTAACTATGTTGGG-TTTT- 238 CATGAATCCTTGCAGCACTGTC PV1LF CTTGCCCAGGCTTGTGTAA 239 PV1LR CCTGGCAATGAGCTACAAGC 240 PV2F3 AGTTATCTGACCACCCCCATGCC 241 PV2R3 CCAACTTAGCCAGTTGGCTATA 242 PV2FIP CCCAACATAGTTAGTACCGGGT -TTTT- 243 CATCCAGTAGCAGTCATGCAGA PV2RIP CCTGGCAATGAGCTACAAGCTG-TTTT- 244 AACTTAGCCAGTTGGCTATACC PV2LF CCAGGCTTGTGTAAGTCTTCAC 245 PV2LR CAGTGCTGCAAGGATTCATGACT 246 JEV JEF3 CACGGCCCAAGCCTCGTCTA 247 JER3 CGGCGCTCTGTGCCTAGTAGCTG 248 JEFIP TCGAGGGGGCTTGGGCCGCA-TTTT- 249 GTGTAAGGACTAGAGGTTAG JERIP GAGGAGGTGGAAGGACTAGA-TTTT- 250 GTTGAGATAGAGCAGAAGAT JELF TGTTGTTTCCACGGGGTCTCCT 251 JELR TTGACACCTGGGAATAGACTGG 252 JE1F3 CCAGGAGGACTGGGTTAACA 253 JE1R3 AGTAGCTGATGTTGAGATAG 254 JE1FIP TTGTTTCCACGGGGTCTCCT-TTTT- 255 CACGGCCCAAGCCTCGTCTA JE1RIP TGCGGCCCAAGCCCCCTCGA-TTTT- 256 GAAGATCTCCCAGTCTATTC JE1LF CTAACCTCTAGTCCTTACAC 257 JE1LR CTAGAGGTTAGAGGAGACCCCG 258 SARS CoV SA1F3 TAC TGT CGT TGA CAA GAA ACG A 259 SA1R3 GCT CTA CTA GAC CAC AAG TGC C 260 SA1FIP GAC GAA ACC TAG GTA TGC TG-TTTT-ACT 261 CGT CCC TCT TCT GCA GA SA1RIP GAT GGA GAG CCT TGT TCT TG-TTTT-ACT 262 AGC ACG TCT CTA ACC TG SA1LF GAT CGA CTG CAA CAC GGA CG 263 SA1LR CAC ACG TCC AAC TCA GTT TGC C 264 SA2F3 TGG GAG ATT CTC AAA TTT CTC A 265 SA2R3 TGC CTT AAG AGG CAT GAG TAG T 266 SA2FIP CCA GCG ATA GTG ACT TGA TC-TTTT-GTC 267 AAG GGT CAA ATA CAG GT SA2RIP TGC GAT CAC TCA ACT TAG GT -TTTT-TGC 268 TCC TTG CCA CGT ATA CA SA2LF ATG CAC ATT TCG AGT GCC TTG 269 SA2LR GAA GTC TTC ATC GCT CAA AGC A 270 SA3F3 CAC ATG ATG TTT CAT CTG CAA T 271 SA3R3 TTG TGA TAG CCA CAT TGA AGC G 272 SA3FIP TTC TGT GAA TTA TAA GGT GA-TTTT-ATA 273 GGC GTT GTA AGA GAA TT SA3RIP AAT CTT AGG ATT GCC TAC GC -TTTT-GAC 274 ATT ACA AGA GTG TGC TG SA3LF TCC AAG CAG GAT TGC GTG TAA G 275 SA3LR CAC AGG GTT CTG AAT ATG ACT A 276 TRY TCF3 CAT GCC TTC CCT CAA CTC ACG G 277 TCR3 GTG TCA TCG TTT GCA GTG TGG A 278 TCFIP GTG CGG TCT AAG AAT TTC AC-TTTT-ATC 279 CAG GAA TGA AGG AGG GT TCRIP ACT ACA GCG AAG GCA TTC TT-TTTT-ATG 280 GTC TCT AAT CAT CTT CG TCLF GAC GCA CCA GTA CGT TCT CC 281 TCLR CTC AAT CAA GAA CCA AAG TGT G 282 TRbF3 AGA AGT CAT TTC AGG AAT CTG C 283 TRbR3 CCT GAA TGC GAC GCC ATG CCT C 284 TRbFI GCA TCG TGA AGG TTA CGT AG-TTTT-AAT 285 CAA GGA CGC GAA GCG CC TRbRI ACT TGG AGG ACG CCG AAG CC-TTTT-GTT 286 TGT CGA GGT TCT CGT GG TRbLF GTC CTC GCA GTG TTG CTT AA 287 TRbLR GGT TCG CCA CGC AGA AGG AG 288 TRbrF3 AAG TAC CTT GGC GCT CGC G 289 TRbrR3 TGC GTT GAG TAC GCA TCT TG 290 TRbrFI TGC AAA CCT TCT TGA CGG GC-TTTT-CTA 291 AAG CTG CTG GCA GTG CC TRbrRI GCA GAC GTC GCA GGA ATC GC-TTTT-ACT 292 ATG TTT GAC GCC GCG GC TRbrLF CTT CGT CAA AGG CGG TGC CA 293 TRbrLR CAA GTA TCG GCA GCA ACC GA 294 ZKV ZK1-F3 GGA TTT GGA AAC GAG AGT TT 295 ZK1-R3 CTA TTG ATG AGA CCC AGT GA 296 ZK1-FIP GCC CCC AAA GGG GCT CAC AC-TTTT-GGA 297 TTC CGG ATT GTC AAT AT ZK1-RIP GAG GCT GCC AGC CGG ACT TC-TTTT-GCT 298 TGA TTG CCG TGA ATC TC ZK1-LF GGG CTA CTC CGC GTT TTA GC 299 ZK1-LR GCT GGG TCA TGG GCC CAT CA 300 ZK2-F3 CTT GAC TAT GAA TAA CAA GCA CT 301 ZK2-R3 AAG TGG CCA GAG GAC AGC CT 302 ZK2-FIP TCC TTG AAC TCT ACC AGT GC-TTTT-GAC ATT 303 CCA TTA CCT TGG CA ZK2-RIP GGC AAA CTG TCG TGG TTC TA-TTTT-TCA 304 GCC TCC AGA GCT CCA GC ZK2-LF GTG GAG TTC CGG TGT CTG CC 305 ZK2-LR GGA GCA GTT CAC ACG GCC CT 306

This novel Lysis-Reaction Buffer—LRB; ˜7.8-pH 8.0) is sensitive, robust and thermostable and formulated to simultaneously perform lysis and real-time amplification of nucleic acids. The buffer can be stored at room temperature. The LRB contains about 0.1-0.4% Triton-X 100; 10-20% Sucrose; 0.1-1M Trehalose; 5-40 mM Tris-HCl; 5-20 mM KCl; 5-20 mM (NH4)2SO4; 5-12 mM MgSO4; 1-3.0 mM each dNTPs; 1-5 mM Tris-Acetate; and 5-12 mM Potassium-Acetate.

Example 2

RT-LAMP Assay for Rapid Detection and Genotype-Identification of Hepatitis C Virus 1-6.

The subject matter of this example is included in Nyan and Swinson (International Journal of Infectious Diseases; DOI: http://dx.doi.org/10.1016/j.ijid.2015.12.002) that is referenced in part.

Introduction

Hepatitis C virus (HCV) is a single-stranded RNA virus of the Flaviviradae family (Moratorio et al., Virol J. 4: 79, 2007). Transmitted through modes including injection drug use (IDU), contaminated needle-stick injuries, and unsafe blood transfusion, infection with HCV may lead to chronic-active hepatitis and hepatocellular carcinoma (Ghany et al., Hepatology 4:1335-1374, 2009; Liang et al., Ann. Int. Med. 132:296-305, 2000; NIH Consensus Statement on Management of Hepatitis C; NIH Consens. Sci. Statements 19:1-46, 2002) Approximately 185 million people are infected with HCV worldwide, with developing countries of Sub-Saharan Africa, Asia, North and South America, and the Middle East mostly affected (Messina et al., Hepatology 61:77-87, 2015; Gower et al., J Hepatol 61: S45-57, 2014; Zein et al., Clin Microbiol Review 13: 223-35, 2000). There are 7 major genotypes of HCV with 67 subtypes found in different regions of the world (Smith et al., Hepatology 59: 318-27, 2014; Lamballerie et al., J Gen Virol 78: 45-51, 1997; Simmonds et al., Hepatology 19: 1321-24, 1994). Globally, HCV genotype 1 is the most common, accounting for about 46% of all infections. This is followed by genotype 3 (22%) and genotypes 2 and 4, each accounting for 13% of global HCV burden (Messina et al., Hepatology 61:77-87, 2015; Gower et al., J Hepatol 61: S45-57, 2014; Zein et al., Clin Microbiol Review 13: 223-35, 2000). Detection of HCV infection in blood-derivatives and identification of the genotypes are therefore important in clinical diagnostics and antiviral treatment, ensuring blood safety, and providing epidemiological information about HCV prevalence (Infectious Diseases Society of America—IDSA. www.hcvguidelines.org 1-100, 2014; De Leuw et al., Liv. Intl. 31: Suppl. 1: 3-12; Etoh et al., BMC Res Notes 24: 316, 2011).

A plethora of molecular diagnostic methods have been designed and used for detection and genotyping of HCV infection. While these test are highly sensitive, they remain expensive, laborious, and require well-trained personnel as well as sophisticated laboratory facilities. (Rho et al., Journal of Microbiol 46: 81-87, 2008; Nolte et al., J Clin Microbiol. 33: 1775-78, 1995; Sábato et al., J Clin Microbiol 45: 2529-36, 2007; Duarte et al., PloS One 5: pii, e12822, 2010). Further, application of these tests may be limited in their ability to detect and simultaneously identify the specific HCV genotypes (De Keukeleire et al., Int J Infect Dis 15: pii: S1201-9712, 2015). Besides, several (reverse transcription) loop mediated isothermal amplification (RT)-LAMP assays have been designed for detection of various pathogens including HCV, but they detect a limited amount of genotypes and rarely demonstrate genotype identification of the pathogens targeted for detection (Notomi et. al., Nucleic Acids Res 28: E63, 2000; Nagamine K, Hasse T, Notomi, T. 2002. Accelerated reaction by loop-mediated isothermal amplification using loop primers. Mol Cell Probes. 16: 223-29; Blomström et al., J Virol Methods 147: 188-93, 2008; Kargar et al., Indian J Virol 23: 18-23, 2012; Yang J, et al., Arch Virol 156: 1387-96, 2011; Wang et al., FEMS Immunol Med Microbiol 8: 144-47, 2011; Sun et al., B Angew Chem Int Ed Engl 53: 8088-92, 2014).

Several reports have been published regarding RT-LAMP assays that utilized the HCV 5′ non-coding region (5′-NCR) for primer design and detection of HCV-RNA (Kargar et al., Indian J Virol 23: 18-23, 2012; Yang J, et al., Arch Virol 156: 1387-96, 2011; Wang et al., FEMS Immunol Med Microbiol 8: 144-47, 2011; Sun et al., B Angew Chem Int Ed Engl 53: 8088-92, 2014). Unfortunately, these works are limited to detection only and demonstrate no pattern formation of the bands, thereby hindering clear determination of true positive detection, contamination, or cross-reactivity. Also, RT-LAMP assays traditionally rely on electrophoretic gel end-point analysis of banding-pattern to determine positive amplification. Therefore, it is important that laddering of RT-LAMP amplicons are arranged in clear and distinct patterns to enable easy analysis and interpretation of amplification results.

This study reports the development of the first RT-LAMP method for detection and simultaneous genotype-identification of HCV genotypes 1-6. The assay is simple, sensitive, and performed on the molecular basis of auto cycling strand-displacement DNA synthesis which produces long stem-loop products of multiple inverted repeats under isothermal amplification (Notomi et. al., Nucleic Acids Res 28: E63, 2000; Nagamine K, Hasse T, Notomi, T. 2002. Accelerated reaction by loop-mediated isothermal amplification using loop primers. Mol Cell Probes. 16: 223-29; Blomström et al., J Virol Methods 147: 188-93, 2008; Kargar et al., Indian J Virol 23: 18-23, 2012). The amplification process is rapid and accomplished in less than 60 minutes, utilizing two thermostable enzymes and 2-3 sets of oligonucleotides. The oligonucleotides target conserved as well as sparsely polymorphic sequences in the 5′-NCR of the HCV genome (Bukh et al., Proc. Natl. Acad. Sci. USA 89: 4942-46, 1992) (Table 1), producing distinctly clear banding-pattern that indicate positive detection for possible target identification. In this study, a new approach to HCV detection and genotype-identification is introduced and discussed.

Materials and Methods

Nucleic Acid Standards and Plasma Panels

Quantified Armored RNA standards of HCV 1a, HCV 1b, and HCV2ac, human immunodeficiency virus (HIV) 1B, dengue virus (DENV) 1, and West Nile virus (WNV) were purchased from Asuragen (Austin, Tex., USA). HCV genotyping plasma panels of WHO International Standard were used in the assay development. The panels included HCV Worldwide AccuSet Performance Panel 0810-0173 (SeraCare, Milford, Mass., USA), the Worldwide HCV Performance Panel WWHV303 (SeraCare, USA), and the AcroMetrix HCV Genotyping Panel (Applied Biosystems/Life Technologies, Grand Island, N.Y., USA). Also, Hepatitis B virus (HBV) plasma panel of WHO International Standard (Applied Biosystems/Life Technologies, USA) was used as control in the assay development.

Diagnostic Genotyping Assay

Detection and identification of HCV was performed by loop-mediated reverse-transcription isothermal amplification in a 25 μL total reaction mixture. The mixture comprised of 12.5 μL of 2× Mannitol-Acetate-Buffer (MAB) (Nyan et al., Clin Infect Dis 59: 16-23, 2014) 1 μM each of primers FIP and RIP, 0.6 μM each of primers LF and LR, 0.5 μM each of primers F3 and R3, 8 Units of Bst DNA polymerase (New England Biolabs, MA, USA), 5 U of cloned-AMV reverse-transcriptase and 10 U of RNaseOut (Invitrogen, Md., USA). RNA template volume of 5 μL was applied to the reaction. A no-template (water) control was included in all experiments. Positive controls included known genotypes of HCV-RNA standards. HIV, DENV, WNV, hepatitis B virus (HBV) DNA (OptiQuant-AcroMetrix/Life Technologies, Benicia, Calif., USA), and normal human plasma were used as assay negative controls. Reactions were performed at 63.5° C. for 30-60 minutes on a portable digital heat-block, the MyBlock Mini Dry Bath (Benchmark Scientific, Edison, N.J., USA) and terminated by placing reaction tubes on ice.

Results

Detection and Analysis of Products

Total RNA extracts of HCV genotypes 1-6 were subjected to isothermal amplification. Electrophoretic analysis of reaction products demonstrated positive amplification of HCV RNA by primer sets DN1 and DN2. The oligonucleotides produced a ladder-like banding pattern common to HCV genotypes 1-6, while the assay reaction was negative to DENV, WNV, HIV, and HBV as confirmed by the absence of banding pattern (FIG. 1A and Supplementary Figure S1A). For rapid naked-eye visualization of results, GelGreen DNA intercalating dye was added to the reaction tubes which revealed an intense fluorescence glow in tubes with amplified RNA as compared with the no-template control (NTC), DENV, WNV, HIV, and HBV (FIG. 1B and Supplementary Figure S1B).

Specificity and Genotype Identification

The assay specificity and cross-reactivity of the primers were evaluated by amplification and gel electrophoretic analysis. As observed on the gels, the primers detected only HCV RNAs, but reacted negative to nucleic acids of DENV (or D), WNV (or W), HIV, and HBV (FIG. 1A and Supplementary Figure S1). Interestingly, primer set DN3 reacted positive to HCV genotypes 1, 3, 4, 5, and 6, producing banding-pattern of amplicons that were unique to each genotype detected, although weakly positive for HCV-3 (FIG. 1C). Differences in banding-patterns were identified by keen observation of the pattern locations relative to the molecular marker, size of the bands within the patterns, spacing of each group of patterns, and the laddering-shift of the patterns as illustrated by the color lines between the duplicate samples (FIG. 1C). When clinical donor specimens were tested using primer set DN3, the results revealed detection of HCV-1 and HCV-6 (FIG. 2, Supplementary Figure S2, and Supplementary Table S1).

Assay Sensitivity

The assay's sensitivity and LOD were determined by testing serial dilutions of HCV-RNA (10⁵-0.1 IU/r×n). Results of electrophoretic analysis demonstrated detection of 10 IU/r×n of HCV-RNA (FIG. 3A). Addition of GelGreen fluorescent dye to the reaction-tubes revealed fluorescent glow with decreasing intensity that corresponded to the level of HCV-RNA amplified (FIG. 3B). Probit test of HCV-RNA replicates demonstrated a 100% detection rate for 10⁵, 10⁴, 10³, and 10² IU; 80% detection rate for 50 IU; and, 40% detection rate for 10 IU. One (1 IU) and 0.1 IU of HCV-RNA were not detected (Table 2A).

TABLE 2 Probit data: Test of replicates of HCV RNA serial dilutions HCV RNA Number of Number of Percent Dilutions Replicates Positive Positive (IU) Tested Reactions (%) 10⁵ 6 6 100 10⁴ 5 5 100 10³ 5 5 100 10² 5 5 100 50 5 4 80 10 5 2 40  1.0 5 0 0  0.1 5 0 0 Time-Course of Detection

In order to determine the time point at which amplification of HCV-RNA occurred, 10 and 50 IU of RNA were tested in the isothermal amplification reaction at designated time-points. Results of electrophoretic analysis of reaction products revealed amplification of 10 IU/r×n of RNA at 60 minutes, while amplification of 50 IU/r×n was observed at 40 minutes (FIG. 5).

Detection and Identification of HCV in Clinical Specimens

In order to determine the clinical applicability of the RT-LAMP-genotyping assay, total RNA was extracted from 171 clinical donor specimens and tested using primer set DN3. Of the 71 HCV-positive clinical donor specimens tested, the assay detected a total of 65 HCV-infected specimens. That is, 58 plasma specimens reaction was positive for HCV-1; two plasma specimens tested positive for HCV-6; two of the known HCV-3 serum specimens tested positive; the 3 known HCV-4 plasma specimens also tested positive, while a total of 6 HCV-infected specimens reacted negative. All healthy human plasma specimens (n=100) tested negative (FIG. 2 and Supplementary Figure S2; Table 2B; Supplementary Table S1). As presented in Table 2C, the assay demonstrated a diagnostic sensitivity of 91.5% with a confidence interval (CI) of 82.5% to 96.8%, while the specificity was 100% with a CI of 96.3% to 100%.

TABLE 3 Evaluation of HCV RT-LAMP genotyping assay with donor plasma and serum specimens Sample Specimen RT-LAMP- HCV Genotype ID Type Results Identified 1 Plasma Positive 1 2 Plasma Positive 1 3 Plasma Positive 1 4 Plasma Positive 1 5 Plasma Positive 1 6 Plasma Positive 1 7 Plasma Positive 1 8 Plasma Positive 1 9 Plasma Positive 1 10 Plasma Positive 1 11 Plasma Positive 1 12 Plasma Positive 1 13 Plasma Positive 1 14 Plasma Positive 1 15 Plasma Positive 1 16 Plasma Positive 1 17 Plasma Negative NA 18 Plasma Positive 1 19 Plasma Positive 1 20 Plasma Positive 1 21 Plasma Positive 1 22 Plasma Positive 1 23 ^(f)Serum Positive 4 24 ^(f)Serum Positive 4 25 *Plasma Positive 3 26 *Plasma Positive 3 27 *Plasma Negative NA 28 ^(f)Serum Positive 4 29 Plasma Positive 1 30 Plasma Negative NA 31 Plasma Negative NA 32 Plasma Positive 1 33 Plasma Positive 1 34 Plasma Positive 1 35 Plasma Negative NA 36 Plasma Positive 6 37 Plasma Positive 1 38 Plasma Positive 1 39 Plasma Positive 1 40 Plasma Positive 1 41 Plasma Positive 1 42 Plasma Positive 1 43 Plasma Positive 1 44 Plasma Positive 1 45 Plasma Positive 1 46 Plasma Positive 1 47 Plasma Positive 1 48 Plasma Positive 1 49 Plasma Positive 1 50 Plasma Positive 1 51 Plasma Positive 6 52 Plasma Positive 1 53 Plasma Positive 1 54 Plasma Positive 1 55 Plasma Positive 1 56 Plasma Positive 1 57 Plasma Positive 1 58 Plasma Positive 1 59 Plasma Positive 1 60 Plasma Positive 1 61 Plasma Positive 1 62 Plasma Positive 1 63 Plasma Negative NA 64 Plasma Positive 1 65 Plasma Positive 1 66 Plasma Positive 1 67 Plasma Positive 1 68 Plasma Positive 1 69 Plasma Positive 1 70 Plasma Positive 1 71 Plasma Positive 1 Total infected Infected Infected Percent of infected specimens specimens specimens specimens tested detected negative detected positive detected (n = 71) (n = 6) (n = 65) (91%) Healthy Healthy Healthy Percent of plasma specimens specimens healthy specimens specimens detected negative detected positive detected (n = 100) (n = 100) (n = 0) negative (100%) Total clinical specimens tested (n = 171) Positive detection (+); *Plasma specimens previously identified to be HCV3-positive; ^(f)Serum specimens previously identified to be HCV4-positive; Detection of HCV RNA with Heat-Treated Plasma Specimens

The assay was also investigated for its ability to amplify viral nucleic acid from heat-treated specimens without RNA extraction. When serial dilutions of heated plasma specimens were tested in the amplification reactions, electrophoretic results demonstrated detection of HCV RNA (10⁶-10⁴ IU/r×n) as confirmed by the presence of banding-patterns (Supplementary Figure S3).

Discussion

Hepatitis C virus (HCV) is a major health care problem worldwide. HCV detection and genotypes identification provide an important insight into the clinical progression of liver disease, response to antiviral therapies, and the dynamics of HCV global epidemiological profile. This study has demonstrated the performance of a specific and simple isothermal amplification assay for rapid detection and genotype-identification of HCV infection in plasma and serum. This work describes the first RT-LAMP assay that detects 6 HCV using single primer sets such as DN1 and DN2. This assay demonstrates advantages over labor-intensive methods that require heavy equipment and multiple diagnostic steps for HCV detection and genotype identification (Albertoni et al., Braz J Infect Dis 14: 147-52, 2010; Detmer et al., J. Clin Microbiol 34: 901-907, 1996; Kotwal et al., Proc Natl Acad Sci. 89: 4486-89, USA 1992; Hara et al., J Clin Microbiol 51: 1485-89, 2013; Shemis et al., Hepat Mon 12: 265-70, 2012) Conducted as a one-step-procedure, this assay also obviates the need for extra cDNA-synthesis and restriction-digest steps for genotype identification. In this assay, both synthesis and amplification of the HCV-RNA were performed in a single reaction-tube, using a single temperature. Additionally, the assay detected and distinguished the HCV-genotypes without requiring post-amplification genotyping procedures such as restriction enzyme analysis, reverse hybridization, or nested RT-PCR (Sun et al., B Angew Chem Int Ed Engl 53: 8088-92, 2014; Albertoni et al., Braz J Infect Dis 14: 147-52, 2010; Detmer et al., J Clin Microbiol 34: 901-907, 1996; Kotwal et al., Proc Natl Acad Sci. 89: 4486-89, USA 1992; Hara et al., J Clin Microbiol 51: 1485-89, 2013; Shemis et al., Hepat Mon 12: 265-70, 2012). Moreover, this assay successfully amplified HCV-RNA utilizing heated specimens without conventional RNA extraction (Supplementary Figure S3). This method of substrate preparation enhances the rapidity of detection and may provide a cost-saving approach for laboratories in resource-limited settings. Notwithstanding its time-saving nature and cost-effectiveness, further improvements in this method of template preparation is required.

The data presented in this study have demonstrated a reverse transcription isothermal amplification assay with the capability to detect HCV infections at the genotypic level. Due to its sensitivity, specificity, and lack of requirements for expensive equipment, this assay is potentially suitable for field and point-of-care use in resource-limited settings and HCV-endemic regions of the world.

Example 3 Real-Time Quantitative Isothermal Multiplex Assay for Pathogen Detection

The subject matter of this example is included in Nyan and Swinson (Nature Scientific Reports; doi:10.1038/srep17925) that is referenced in part.

Introduction

The global emergence or re-emergence of a plethora of bacterial, viral, and parasitic pathogens with outbreaks of virulent infections have challenged the diagnostic capabilities of health care systems globally, mainly in resource-limited environments (Baize et al., N Engl J Med. 371: 1418-1425, 2014; Duda et al., J Int AIDS Soc 0.17:19045, 2014). This have since underscored the need for simple, but efficient diagnostic tools that would enable rapid detection, quantitation, and simultaneous identification of pathogens, particularly those presenting similar on-set clinical symptoms. Such differential diagnostic tools would enable health care workers to institute the requisite measures including isolation and timely therapeutic interventions. Hepatitis B virus (HBV), Hepatitis C virus (HCV), and the emerging Hepatitis E virus (HEV) together infect over 400 million people globally and may lead to chronic active hepatitis and hepatocellular carcinoma (CDC. MMWR. 58 (No. SS-3), 2009; Huy and Vernavong. AIDS Res Treat. 2014:581021. doi: 10.1155/2014/581021). Infection with the human immunodeficiency virus (HIV) compromises the immune system, while Dengue virus (DENV), West Nile Virus (WNV), and Chikungunya virus (CHIKV) infections may lead to hemorrhagic fever, neuroinflammatory, and arthritic conditions in infected patients, respectively (Naze. et al. J Virol Methods. 162:1-7, 2009; Omarjee. et al. Euro Surveill. 19. pii: 20753, 2014). The world has recently witnessed the ravaging effect of the Ebola virus disease outbreak in West Africa. Other pathogens such as Marburg virus (MBV), Yellow fever virus (YFV), Lassa fever virus (LFV), Plasmodium species, Chikungunya virus (CHIKV), Japanese Encephalitis virus (JEV), Middle Eastern Respiratory Syndrome Corona virus (MERS CoV), Mycobacterium species (MTB), Severe Acute Respiratory Syndrome Corona virus (SARS CoV), Cytomegalovirus (CMV), Parvovirus (PAB19), Plasmodium species (PLM), Leishmania species (LE), and Trypanosoma (TRY) have also caused diseases of untold human sufferings (Feldmann and Geisbert, The Lancet. 377:849-862, 2011; Dummer et al., J. Infect. Dis. 152, 1182-1191, 1985; Alvar et al., PLoS One. 7:e35671, 2012; Zaki et al., N Engl J Med. 367:1814-1820, 2012; WHO. Global tuberculosis report 2014, 2014). Hence, the need for a simple and cost-effective assay capable of simultaneously detecting and identifying the presence of multiple bacterial, viral and parasitic pathogens in patients or those circulating in particular endemic regions cannot be overemphasized.

Several amplification-based multiplex test-methods including quantitative reverse-transcription polymerase chain reaction (qRT-PCR) have been developed and used to detect and quantitate pathogen load (Chao et al., J Clin Microbiol. 45, 584-589, 2007; Hennechart-Collette et al., J Appl Microbiol. 116, 179-190, 2014). However, these methods exhibit drawbacks as they are time-consuming, expensive, and require the use of heavy equipment and highly trained personnel to perform. Despite their outstanding performance, these characteristics present limitations in their point-of-care use in field and resource-limited environments. Besides, many (reverse transcription) loop-mediated isothermal amplification assays (RT)-LAMP have been designed, but have hardly demonstrated multiplexing capability to simultaneously detect different types of viruses (Notomi et al. Nucleic Acids Res. 28: e63, 2000; Blomström et al. J Virol Methods. 147: 188-193, 2008; Zhang et al. J Clin Microbiol. 48: 2116-2121, 2010; Pan et al. BMC Infect Dis. DOI: 10.1186/1471-2334-12-254, 2012). Those (RT)-LAMP methods that claim multiplexing capability are restricted to detecting only one type of pathogen (e.g. viruses—Influenza A), rely on an opened-tube analysis of amplification products for detection and quantitation, and utilize on gel-end point analysis for distinction of viruses, and based on non-specific fluorescene chemistries such as SYBR Green, GelGreen, calcein or hydroxy naphthol blue that are target-independent (Jung et al., Analytica Chimica Acta. 853, 541-547, 2015; Tomita et al., Nat. Prot. 3, 877-882, 2008; Beauchamp et al., Anal. Methods. 4, 4187-4192, 2012; Wang et al., Virology Journal 8, 108, 2011).

The method herein reported describes the development of the first real-time quantitative multiplex fluoro-isothermal amplification assay for detection and identification of bacterial, viral and parasitic pathogens, as well as simultaneous quantification of pathogen burden in biological samples (e.g. blood plasma and serum). The method utilizes 2 to 3 pairs of pathogen-specific oligonucleotides including fluorogenic oligonucleotides that produces real time nucleic acid amplification results of graphs representing different pathogens or different genotypes/species of a particular pathogen. This also enables instant visualization of different colors for different pathogens as well as detection and quantitation.

This assay is based on fluorogenic auto cycling strand-displacement DNA synthesis (Walker et al. Nucleic Acids Res. 20: 1691-1696, 1992; Notomi et al. Nucleic Acids Res. 28: e63, 2000; Marras. Mol Biotechnology. 3 8: 247-255, 2008). Specially developed pathogen-specific flourophores and oligonucleotides simultaneously hybridize to the target nucleic acids in a sample and emit distinctive detection signals. The amplification process is accomplished within about 10 to 40 minutes, utilizing a portable real-time multichannel fluorospectrophotometric heat source or device. Here, a novel approach at multiple pathogen detection, identification, and quantitation by isothermal real time amplification is reported. This new detection method could be useful in alleviating differential diagnostic challenges in resource-limited environments of the developing as well as developed world settings clinical and point-of-care settings.

Experimental Methods

Preparation of Samples for Amplification

DNA and total RNA are extracted from standard reference and genotyping plasma panels of WHO International Standard (OptiQuant-AcroMetrix/Life Technology, Benicia, Calif., USA and Sera Care, Milford, Mass., USA, respectively). Nucleic acids are also extracted from clinical donor plasma specimens using the QiaAmp Viral RNA mini kit and the QiAamp DNA Blood Mini Kit modified protocol (Qiagen, Germantown, Md., USA) as previously described (Nyan et al. Clin Infect Dis. 59:16-23, 2014). Second, clinical specimens are also subjected to lysis utilizing the New Lysis Buffer, making samples directly available for amplification without further extraction procedure. Third, samples are directly applied in the reaction mixture which enables lysis and simultaneous amplification of nucleic acid due to the lytic effect of the novel reaction buffer.

Design of Oligonucleotides

Several full-length sequences of pathogens including bacteria, viruses, and protozoans pathogens were obtained from the EMLB and GenBank databases and analyzed using CLUSTALW-2 and CLUSTAL-Omega. Pathogen-specific Forward outer primer (F3), Reverse outer primer (R3), Forward Inner primer (FIP), Reverse Inner primer (RIP), Loop Forward primer (LF), and Loop Reverse primer (LR) were manually designed. Further, the F3, R3, LF, or LR primers were designed as bi-labeled loop fluorescent probes. The loops are held in a hairpin-loop conformation by 5 to 7 nucleotides long complementary stem-sequences at both ends (5′-3′ or vice versa) and tagged with desirable reporter-fluorophore or quencher. Fluorophores include 6-carboxyfluorescein (6-Fam), tetrachlorofluorescein (Tet), or Texas-Red or other desirable reporter dyes, while quenchers include black hole quencher-1, 2, and 3 (BHQ1, 2, and 3) or other desirable quenchers.

Standards and Controls

Quantitated HIV, HCV, and HBV plasma panels of WHO International Standards, (OptiQuant-AcroMetrix/Life Technology, and Sera Care, USA) are subjected to nucleic extraction. Armored RNA standards of Dengue and West Nile viruses (Asuragen, Tex., USA) are also used as standard controls. DNA and RNA were serially diluted in nuclease-free water, and used in amplification reactions.

Multiplex Amplification Assay

Nucleic acid detection, identification, and quantitation of the various targeted pathogens is performed by real-time (reverse-transcription)-isothermal amplification process in a 25 μL reaction mixture. The mixture comprises of about 10 to 12.5 μL of Lysis Reaction Buffer (LRB) and a mixed pathogen-specific oligonucleotide sets including pathogen-specific hair-pin loop fluorooligonucleotides (about 0.1 to 1 μM) of the target bacteria, viruses, and/or parasites. About Five (5) units of RnaseOut, 5 U of cloned AMV reverse-transcriptase (Invitrogen, Frederick, USA), and 8-10 Units of Bst DNA polymerase (New England Biolabs, MA, USA), are added to catalyze the reaction. Sample subjected to heat-treatment, lysis buffer treatment or nucleic acid extraction (e.g. EBOV, MERS CoV, HIV, HCV, HBV, TRY, DENV, MTB, WNV, PLM, ZKV, and CHIKV) is applied to the mixture as template volume of 1-10 μL. An assay internal positive control of approximately 100-10⁶ IU per reaction (or equivalent copies per reaction) and no-template (water) control is included in all amplification runs to control for assay efficiency and reagent integrity. Normal human plasma also serves as negative control. Amplification-reactions are conducted at about 60° C. for about 20-40 minutes on a portable real-time (multichannel) fluorospectrophotometric heating device.

Analysis of Results and Quantitation Nucleic Acid

During the process of amplification, results are read on the real-time (multichannel) fluorospectrophotometric heating device. The device reveals simple graphs at different wavelengths (e.g. 400 to 740 nm) having amplitudes that represent fluorescent emission of amplified nucleic acids of a specific pathogen (see illustration in FIG. 9: HIV, HBV, WNV, and HCV; and FIG. 10: HIV, HBV, WNV, PLM, CMV, DENV, TRY, and LE). The quantity of the amplified nucleic acid is calculated by the device against the negative control and a predetermined internal control. Naked eye UV and/or blue-light visualization of reaction tubes reveals fluorescence glow only in reaction tubes with amplified nucleic acid of the pathogens of interest (see FIGS. 8B and 8D). This is applicable to detecting and identifying multiple pathogens of interest.

Specificity and Sensitivity

Assay sensitivity was evaluated by testing 10-fold serial dilutions of quantitated HBV-DNA and HCV-RNA, with results demonstrating detection of approximately 10 IU/reaction of nucleic acid, while the assay has demonstrated a high specificity. Evaluation of the assay diagnostic sensitivity with clinical human plasma specimens (including HIV, WNV, DENV, HBV, and HCV) detection of 36 of 37 (97%) infected specimens when the respective fluorooligonucleotides of HIV, WNV, DENV, HBV, and HCV were used (see table 4). The assay diagnostic specificity was tested using control plasma (n=52) using normal human plasma, plasma infected with Cytomegalovirus and parvovirus against pathogen-specific primers and fluorooligonucleotides of HIV, WNV, DENV, HBV, and HCV, respectively. The results revealed a 100% diagnostic specificity as demonstrated by no detection of negative control samples (see Table 4).

TABLE 3 Clinical donor specimens tested by Isothermal Multiplex Assay Number Isothermal ^(¶)Procleix Specimens Tested Multiplex Assay test A. Negative Clinical specimens Diagnostic Specificity (n = 52) (Test-Negative) Normal Human Plasma 28 28 28 Cytomegalovirus 15 15 15 Parvovirus 9 9 9 Total 52 52 52 Percent Negative 100% 100% B. Positive Clinical Diagnostic Sensitivity Specimens (n = 37) (Test-Positive) Human immuno- 6 5 6 deficiency virus Hepatitis B virus 9 9 9 Hepatitis C virus 10 10 10 Dengue virus 5 5 5 West Nile virus 7 7 7 Total 37 36 37 Percent Positive 97% 100% ^(¶)Procleix data based on selected cohort; Abbreviation: NA, not applicable

The data demonstrate the potential application of this method for detection, identification, and quantification of multiple bacterial, viral and parasitic targets. The assay revealed a high diagnostic sensitivity and specificity (see Table 4). The summation of these results suggest that this assay could be employed for analysis of patients' blood samples, donor screening for blood-borne pathogens, and investigating the epidemiological trend of infectious pathogens in endemic regions.

It should be recognized that the above described embodiments to which the principles of the disclosure applies are possible examples of illustrative implementation, set forth to provide a clear understanding of this disclosure, and should not be considered as limiting the scope of the invention. Many other variations and further modifications are intended to be made to the above described embodiments without departing from the scope of this invention, rather intended to be included within the scope of this disclosure as well as defined and protected by the following claims. 

We claim:
 1. A method of isothermal detection of a plurality of pathogens, the method comprising: providing a sample; extracting nucleic acid from the sample; mixing the sample with amplification or detection reagents; placing the sample mixture on a thermal heating device for a predetermined period of time; amplifying the extracted nucleic acid; and detecting at least two pathogens in real time from the extracted nucleic acid, wherein the step of detecting further comprises: contacting the sample with two or more sets of real time loop-mediated isothermal amplification (LAMP) primers and probes, each primer and probe comprising a nucleic acid sequence having at least 90 to 99% sequence identity to any one of SEQ ID NOs 1-306, wherein the sets are selected from the group consisting of (a) sets of (RT)-LAMP primers specific for HCV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 1-68; (b) sets of (RT)-LAMP primers specific for HBV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 69-86; (c) sets of (RT)-LAMP primers specific for HEV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 87-100; (d) sets of (RT)-LAMP primers specific for HIV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 101-112; (e) sets of (RT)-LAMP primers specific for WNV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 113-118; (f) sets of (RT)-LAMP primers specific for DENV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 119-130; (g) sets of (RT)-LAMP primers specific for CHIKV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 131-143; (h) sets of (RT)-LAMP primers specific for CMV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 144-150; (i) sets of (RT)-LAMP primers specific for PLM nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 151-156; (j) sets of (RT)-LAMP primers specific for EBOV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 157-169; (k) sets of (RT)-LAMP primers specific for MARV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 170-175; (l) sets of (RT)-LAMP primers specific for YFV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 176-181; (m) sets of (RT)-LAMP primers specific for LE nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 182-187; (n) sets of (RT)-LAMP primers specific for LFV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 188-209; (o) sets of (RT)-LAMP primers specific for MTB nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 210-221; (p) sets of (RT)-LAMP primers specific for MERS CoV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 222-235; (q) sets of (RT)-LAMP primers specific for PAB19 nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 236-246; (r) sets of (RT)-LAMP primers specific for JEV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 247-258; (s) sets of (RT)-LAMP primers specific for SARS CoV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 259-276; (t) sets of (RT)-LAMP primers specific for TRY nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 277-294; and (u) sets of (RT)-LAMP primers specific for ZKV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 295-306.
 2. The method of claim 1, wherein the samples contain pathogens comprising at least two or more bacteria, viruses, and/or protozoans for example Chikunguya virus (CHIKV) nucleic acid, Cytomegalovirus (CMV) nucleic acid, Dengue virus (DENV) nucleic, Ebola virus (EBOV) nucleic acid, Hepatitis B virus (HBV) nucleic acid, Hepatitis C virus (HCV) nucleic acid, Human immunodeficiency virus (HIV) nucleic acid, Hepatitis E virus (HEV) nucleic acid, Japanese Encephalitis virus (JEV), Leishmania (LE) nucleic acid, Lassa fever virus (LFV) nucleic acid, Marburg virus (MARV) nucleic acid, Middle Eastern Respiratory Syndrome Corona virus (MERS CoV) nucleic acid, Parvovirus (PAB19) nucleic acid, Plasmodium (PLM) nucleic acid, Severe Acute Respiratory Syndrome Corona virus (SARS CoV) nucleic acid, Trypanosoma (TRY) nucleic acid, West Nile virus (WNV) nucleic acid, Yellow fever virus (YFV) nucleic acid and/or Zika virus (ZKV) nucleic acid.
 3. The method of claim 1, wherein the predetermined period of amplification reaction time comprises a range of about 10 to 40 minutes.
 4. The method of claim 1, wherein the SEQ ID Nos 1-306 comprise at least one of the following: CHIKV nucleic acid, CMV nucleic acid, DENV nucleic, EBOV nucleic acid, HBV nucleic acid, HCV nucleic acid, HIV nucleic acid, HEV nucleic acid, JEV nucleic acid, LE nucleic acid, LFV nucleic acid, MARV nucleic acid, MERS CoV nucleic acid, PAB19 nucleic acid, PLM nucleic acid, SARS CoV nucleic acid, TRY nucleic acid, a WNV nucleic acid, YFV nucleic acid and/or ZKV nucleic acid.
 5. The method of claim 1, wherein the step of extracting the nucleic acid from the sample comprises heating the sample at a temperature of about 30° C. to about 110° C.
 6. The method of claim 1, wherein the step of extracting the nucleic acid from the sample comprises applying a lysis buffer to the sample in ratios of about 1:3 to about 1:100 and incubated for about 2 to about 10 minutes.
 7. The method of claim 1, wherein the sample comprises blood, plasma, serum, urine, saliva, sperm, vaginal fluid, tissue biopsy, vomitus, fine needle aspirate, cerebrospinal fluid, bronchial aspirate, perspiration, mucus, fecal matter, synovial fluid, swabs, lymphatic fluid, tears, tracheal aspirate and/or a surgical specimen.
 8. The method of claim 1, further comprising: contacting the samples with a reverse transcriptase, DNA polymerase, deoxynucleotide, and RNAse inhibitor.
 9. The method of claim 1, wherein the method comprises contacting the sample with: (a) sets of (RT)-LAMP primers specific for HCV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 1-68; (b) sets of (RT)-LAMP primers specific for HBV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 69-86; (c) sets of (RT)-LAMP primers specific for HEV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 87-100; (d) sets of (RT)-LAMP primers specific for HIV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 101-112; (e) sets of (RT)-LAMP primers specific for WNV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 113-118; (f) sets of (RT)-LAMP primers specific for DENV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 119-130; (g) sets of (RT)-LAMP primers specific for CHIKV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 131-143; (h) sets of (RT)-LAMP primers specific for CMV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 144-150; (i) sets of (RT)-LAMP primers specific for PLM nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 151-156; (j) sets of (RT)-LAMP primers specific for EBOV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 157-169; (k) sets of (RT)-LAMP primers specific for MARV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 170-175; (l) sets of (RT)-LAMP primers specific for YFV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 176-181; (m) sets of (RT)-LAMP primers specific for LE nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 182-187; (n) sets of (RT)-LAMP primers specific for LFV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 188-209; (o) sets of (RT)-LAMP primers specific for MTB nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 210-221; (p) sets of (RT)-LAMP primers specific for MERS CoV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 222-235; (q) sets of (RT)-LAMP primers specific for PAB19 nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 236-246; (r) sets of (RT)-LAMP primers specific for JEV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 247-258; (s) sets of (RT)-LAMP primers specific for SARS CoV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 259-276; (t) sets of (RT)-LAMP primers specific for TRY nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 277-294; and (u) sets of (RT)-LAMP primers specific for ZKV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 295-306.
 10. The method claim 1, wherein the sample is contacted with the two or more sets of (RT)-LAMP primers and probes consisting of the nucleic acid of SEQ ID No 1-306 for real time multiplex isothermal amplification of the nucleic acids of two or more of the pathogens in a sample including human immunodeficiency virus (HIV), Ebola virus species (Zaire, Sudan, Tai-Forest, Reston, Bundibugyo), Marburg virus (MBV), Yellow fever virus (YFV), hepatitis-B virus (HBV), Lassa fever virus (LFV), hepatitis-C virus (HCV), hepatitis-E virus (HEV), dengue virus (DENV), Chikungunya virus (CHIKV), Japanese Encephalitis virus (JEV), Middle Eastern Respiratory Syndrome Corona virus (MERS CoV), Mycobacterium species (MTB), Severe Acute Respiratory Syndrome Corona virus (SARS CoV), West Nile (WNV) virus, Cytomegalovirus (CMV), Parvovirus (PAB19), Plasmodium species (PLM), Leishmania species (LE), Trypanosoma species (TRY) and Zika virus (ZKV) nucleic acids.
 11. The method of claim 1, wherein the sample is contacted with the two or more sets of (RT)-LAMP primers and probes consisting of the nucleic acid of SEQ ID No 1-306 in a single reaction vessel for real time multiplex isothermal amplification of the nucleic acids of two or more of the pathogens in a sample at temperature of about 40° C. to about 75° C.
 12. The method of claim 1 for rapid real-time multiplex isothermal detection, identification and quantitation of the presence of two or more of the nucleic acid of SEQ ID No 1-306 of pathogens simultaneously or in parallel in a single reaction vessel in real-time on a portable real-time multichannel fluorospectrophotometric heating device.
 13. The method of claim 1 wherein samples are contacted with the two or more sets of primers and probes comprising nucleic acid sequence having at least 95-99% sequence identity to any one of SEQ ID NOs 1-306 specific for pathogen including EBOV, MARV, HCV, HBV, HIV, LE, PLM, TRY, LFV, MTB, MERS CoV, SARS CoV, CMV, PAB19, DENV, WNV, JEV, YFV, HEV, CHIKV, and ZKV nucleic acid, amplification of the EBOV, MARV, HCV, HBV, HIV, LE, PLM, TRY, LFV, MTB, MERS CoV, SARS CoV, CMV, PAB19, DENV, WNV, JEV, YFV, HEV, CHIKV, and ZKV nucleic acid, thereby producing EBOV, MARV, HCV, HBV, HIV, LE, PLM, TRY, LFV, MTB, MERS CoV, SARS CoV, CMV, PAB19, DENV, WNV, JEV, YFV, HEV, CHIKV, ZKV pathogen-specific amplification signals as dots, amplification, dissociation, and/or melt curves, thereby detecting the presence of EBOV, MARV, HCV, HBV, HIV, LE, PLM, TRY, LFV, MTB, MERS CoV, SARS CoV, CMV, PAB19, DENV, WNV, JEV, YFV, HEV, CHIKV, and ZKV nucleic acid in the sample, measurable in real-time on a portable real-time multichannel fluorospectrophotometric heating device.
 14. The method of claim 1, wherein the two or more sets of (RT)-LAMP primers and probes comprise one or more primers and probes comprising a nucleic acid sequence having at least 95-99% sequence identity to any one of SEQ ID NOs 1-306, wherein at least one primer in the pathogen-specific set of the (RT)-LAMP primers comprises a detectable label that comprises a reporter-fluorophore and fluorescence quencher.
 15. A kit for performing the method according to claim 1, wherein the kit comprises two or more sets of real time loop-mediated isothermal amplification (LAMP) primers and probes, each primer and probe comprising a nucleic acid sequence having at least 90 to 99% sequence identity to any one of SEQ ID NOs 1-306, wherein the sets are selected from the group consisting of (a) sets of (RT)-LAMP primers specific for HCV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 1-68; (b) sets of (RT)-LAMP primers specific for HBV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 69-86; (c) sets of (RT)-LAMP primers specific for HEV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 87-100; (d) sets of (RT)-LAMP primers specific for HIV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 101-112; (e) sets of (RT)-LAMP primers specific for WNV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 113-118; (f) sets of (RT)-LAMP primers specific for DENV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 119-130; (g) sets of (RT)-LAMP primers specific for CHIKV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 131-143; (h) sets of (RT)-LAMP primers specific for CMV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 144-150; (i) sets of (RT)-LAMP primers specific for PLM nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 151-156; (j) sets of (RT)-LAMP primers specific for EBOV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 157-169; (k) sets of (RT)-LAMP primers specific for MARV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 170-175; (l) sets of (RT)-LAMP primers specific for YFV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 176-181; (m) sets of (RT)-LAMP primers specific for LE nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 182-187; (n) sets of (RT)-LAMP primers specific for LFV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 188-209; (o) sets of (RT)-LAMP primers specific for MTB nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 210-221; (p) sets of (RT)-LAMP primers specific for MERS CoV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 222-235; (q) sets of (RT)-LAMP primers specific for PAB19 nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 236-246; (r) sets of (RT)-LAMP primers specific for JEV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 247-258; (s) sets of (RT)-LAMP primers specific for SARS CoV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 259-276; (t) sets of (RT)-LAMP primers specific for TRY nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 277-294; and (u) sets of (RT)-LAMP primers specific for ZKV nucleic acid comprising four to six primers consisting of the nucleic acid sequences of SEQ ID NOs 295-306. 